sample_info.csv

original_sample_id,original_patient_id,flow_id,specimen,label,sublabel,abnormal_percentage,PatientName,Sex,Age,SamplingDate,ReportDate,ReferredBy,Specimen,ClinicalDx,SampleCondition,GatingStrategy,CellsGatedPercentage,GatingRegion,AdjustedCellConcentration,TotalEventAcquisition,InternalControlStatus,SourceFile,CreationTime,FileSizeBytes,LastWriteTime,SantiziedFileName,OriginalFilePath,TechnicalComment,Interpretation,Specimen_Label,SantiziedFileName_LastPart,cluster,Label_Clearning_Note,Age_Group_Label,Remark,OriginalFilePath2,20250523_export,20250524_export
5297838,5127116,5297838_BM_5127116_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,24,2023-10-06,2023-10-11,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,<0.1%,Blasts,1.8×103/μL（dilution:N/A x）,"16,191 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5297838).json,2024-05-22T07:54:16.8124224+08:00,68096,2023-10-11T09:35:39.232+08:00,5297838_5127116_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231006\5297838_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5297838).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable. MDS diagnostic flow score: 1 point.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and there are no myelodysplastic syndrome (MDS)-related features.",BM,4|4,1,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231006\5297838_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5297838).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231006\5297838_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5297838).doc""] = ""5297838_BM_5127116_ClearLLab10C_NO-MALIGNANCY"","
1895390,6628903,0001895390_PB_6628903_ClearLLab10C_MALIGNANCY,PB,Malignancy ,Acute Leukemia,0.758,,男,28,2024.11.20,2024.11.22,XXX,Other: 周邊血,AML,Acceptable,CD45/SSC,75.8%,Blasts,3.3×103/μL（dilution: N/A x）,"47,134 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001895390_AML(T)(PB).json,2024-11-22T15:29:02.986768+08:00,77312,2024-11-22T15:43:34.1956514+08:00,0001895390_6628903_Other: 周邊血_AML_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0001895390_AML(T)(PB)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001895390_AML(T)(PB).doc,"Previous FCM results (2024.05.14.): acute myeloid leukemia (AML), myeloblasts:20%. Immunophenotyping of peripheral blood leukocytes by flow cytometry reveals the presence of a predominant myeloblast population, comprising approximately 75% of the total nucleated cells. These cells are positive for CD34 (bright), CD13, CD33, CD117, CD123, and HLA-DR (partial). Additionally, they are negative for CD10, CD19, CD38, CyCD79a, CyCD3, and MPO. Myeloblasts show aberrant expression of CD5, CD7, and CD56.","Acute myeloid leukemia, residual leukemic cells account for approximately 75.8% of all nucleated cells in the peripheral blood.",PB,4|5,-1,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0001895390_AML(T)(PB)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001895390_AML(T)(PB).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0001895390_AML(T)(PB)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001895390_AML(T)(PB).doc""] = ""0001895390_PB_6628903_ClearLLab10C_MALIGNANCY"","
1895390,5718243,0001895390_BM_5718243_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.2,,男,28,2024-05-08,2024-05-09,XXX,Bone marrow,PNH,Acceptable,CD45/SSC,20.3%,Blasts,3.5×103/μL（dilution: N/A x）,"70,524 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0001895390).json,2024-05-22T08:08:02.8805506+08:00,74240,2024-05-09T16:30:23.7815461+08:00,0001895390_5718243_Bone marrow_PNH_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240509\0001895390_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0001895390).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant myeloblast population, comprising approximately 20% of the total nucleated cells. These cells are positive for CD34, CD13(dim), CD33, CD117, CD123, and HLA-DR. Additionally, they are negative for CD10, CD19, CD38, CyCD79a, CyCD3, and MPO. Myeloblasts show aberrant expression of CD7 and CD56. Normoblasts are increased (46%).",Immunophenotyping are compatible with acute myeloid leukemia (AML).,BM,4|5,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240509\0001895390_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0001895390).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240509\0001895390_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0001895390).doc""] = ""0001895390_BM_5718243_ClearLLab10C_MALIGNANCY"","
1895390,6847122,0001895390_BM_6847122_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.13,,男,29,2025.01.02,2025.01.06,XXX,Bone marrow,Post-treatment follow-up for AML,Acceptable,CD34/SSC,13.0%,Blasts,0.4×103/μL（dilution: N/A x）,"13,695 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001895390_6847122_AML(T).json,2025-01-06T11:30:27.1488062+08:00,72192,2025-01-06T11:52:18.7034602+08:00,0001895390_6847122_Bone marrow_Post-treatment follow-up for AML_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250108\0001895390_6847122_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001895390_6847122_AML(T).doc,"Previous FCM results (2024.11.20.): acute myeloid leukemia (AML), residual leukemic cells account for approximately 75.8% of all nucleated cells in the peripheral blood. Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of an abnormal myeloblast population, comprising approximately 13% of the total nucleated cells. These cells are positive for CD34(bright), CD13(dim), CD33(bright), CD117, CD123, CD200, and HLA-DR. Myeloblasts show aberrant expression of CD5, CD7, and CD56. ※患者骨髓檢體白血球數目<500/μL且流式細胞儀收集有核細胞總數不足20,000顆，可能影響分析靈敏度，報告判讀時請小心。","Acute myeloid leukemia, residual leukemic cells account for approximately 13.0% of total nucleated cells.",BM,4|4,-1,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250108\0001895390_6847122_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001895390_6847122_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250108\0001895390_6847122_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001895390_6847122_AML(T).doc""] = ""0001895390_BM_6847122_ClearLLab10C_MALIGNANCY"","
2116347,6733122,0002116347_BM_6733122_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.31,,女,35,2024.12.10,2024.12.12,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,31.3%,Blasts,5.8×103/μL（dilution:N/Ax）,"94,173 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002116347_AML.json,2024-12-11T17:19:31.3051183+08:00,75776,2024-12-12T11:30:14.7666072+08:00,0002116347_6733122_Bone marrow_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241218\0002116347_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002116347_AML.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals a predominant myeloblast population, comprising approximately 31% of the total nucleated cells. These cells show partial positivity for CD34, dim positivity for MPO, and are positive for CD13, CD33, CD38, CD117, CD123, and HLA-DR. They are negative for CD7, CD10, CD19, CyCD3, and CyCD79a. Granulocytes comprise approximately 55% of the nucleated bone marrow cells. Monocytes constitute less than 1% of bone marrow cells.",Immunophenotyping are compatible with acute myeloid leukemia (AML) with maturation.,BM,4|5,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241218\0002116347_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002116347_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241218\0002116347_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002116347_AML.doc""] = ""0002116347_BM_6733122_ClearLLab10C_MALIGNANCY"","
2116347,7244544,0002116347_BM_7244544_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.149,,女,35,2025.3.26,2025.3.27,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD45/SSC,14.9%,Blasts,12.3×103/μL（dilution:N/Ax）,"135,288 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002116347_7244544_AML(T).json,2025-03-27T15:45:04.42539+08:00,73728,2025-03-27T15:57:38.6805047+08:00,0002116347_7244544_Bone marrow_AML (post-treatment follow-up)_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250331\0002116347_7244544_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002116347_7244544_AML(T).doc,"Previous FCM results (2024.12.18): Immunophenotyping are compatible with acute myeloid leukemia (AML) with maturation. Flow cytometric immunophenotyping of the bone marrow aspirate reveals an abnormal myeloblast population comprising approximately 15% of the total nucleated cells. These cells are positive for CD34, CD13, CD33 (bright), CD38, CD117, CD123 (bright), and HLA-DR. They are negative for MPO, CD10, CD19, CyCD3, and CyCD79a. These myeloblasts exhibit aberrant expression of CD7.",Abnormal myeloblasts account for approximately 14.9% of the total nucleated cells.,BM,4|5,-1,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250331\0002116347_7244544_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002116347_7244544_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250331\0002116347_7244544_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002116347_7244544_AML(T).doc""] = ""0002116347_BM_7244544_ClearLLab10C_MALIGNANCY"","
1451460,5636462,1451460_BM_5636462_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,36,2024-04-16,2024-04-17,XXX,Bone marrow,Pancytopenia,Acceptable,CD38/SSC,8.7%,Plasma cells,0.1×103/μL（dilution:N/Ax）,"17,062 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(1451460).json,2024-05-22T08:06:45.067773+08:00,68096,2024-04-17T17:02:26.346+08:00,1451460_5636462_Bone marrow_Pancytopenia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240418\1451460_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(1451460).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals a population of lymphoid cells (55.6%) with normal expression and no signs of surface light-chain restriction. Among the cells analyzed using CD38/SSC gating, plasma cells account for approximately 8%. Additionally, myeloblasts comprise less than 0.1% of the total nucleated cells, and other immunophenotyping results are unremarkable.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and plasma cells are increased.",BM,4|4,-1,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240418\1451460_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(1451460).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240418\1451460_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(1451460).doc""] = ""1451460_BM_5636462_ClearLLab10C_NO-MALIGNANCY"","
1029026,6922891,0001029026_PB_6922891_ClearLLab10C_MALIGNANCY,PB,Malignancy ,Acute Leukemia,0.9,,女,43,2025.01.17,2025.01.20,XXX,Other:周邊血,B-ALL suspected,Acceptable,CD45/SSC,90.0%,Blasts,3.5 ×103/μL（dilution:N/Ax）,"98,451 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001029026_3922891_BALL(PB).json,2025-01-20T14:17:05.6584816+08:00,72704,2025-01-20T14:41:13.1933332+08:00,0001029026_6922891_Other:周邊血_B-ALL suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0001029026_6822891_BALL(PB)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001029026_3922891_BALL(PB).doc,"Immunophenotyping of peripheral blood leukocytes by flow cytometry reveals a predominant abnormal B-cell population, comprising approximately 90% of all analyzed cells. These blast cells exhibit small to medium nuclear sizes, as indicated by the forward-scatter signal, and express CD10, CD19, CD38, CyCD79, CD200, and HLA-DR. Additionally, they aberrantly express CD123 while lacking CD34 expression.",Immunophenotyping are compatible with precursor B-acute lymphoblastic leukemia.,PB,4|5,-1,B-ALL,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0001029026_6822891_BALL(PB)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001029026_3922891_BALL(PB).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0001029026_6822891_BALL(PB)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001029026_3922891_BALL(PB).doc""] = ""0001029026_PB_6922891_ClearLLab10C_MALIGNANCY"","
2218495,6479604,0002218495_BM_6479604_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,43,2024.10.21,2024.10.22,XXX,Bone marrow,"ITP, R/O MDS",Acceptable,CD34/SSC,0.4%,Blasts,9.6×103/μL（dilution:N/Ax）,"110,078 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002218495_MPN.json,2024-10-22T12:15:57.0104079+08:00,69120,2024-10-22T15:32:15.9180637+08:00,"0002218495_6479604_Bone marrow_ITP, R/O MDS_4|4.json",\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0002218495_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002218495_MPN.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.4% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point.","Myeloid blasts comprise approximately 0.4% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,7,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0002218495_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002218495_MPN.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0002218495_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002218495_MPN.doc""] = ""0002218495_BM_6479604_ClearLLab10C_NO-MALIGNANCY"","
1206993,5411046,1206993_BM_5411046_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,44,2024-01-22,2024-01-22,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,<0.1 %,Blasts,8.9 ×103/μL（dilution:N/Ax）,"135,070 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(1206993).json,2024-05-22T08:02:54.0996349+08:00,67584,2024-02-05T16:49:42.178+08:00,1206993_5411046_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240122\1206993_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(1206993).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. These cells exhibited normal expression for CD34, CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and no residual leukemic cells were found in bone marrow.",BM,4|4,-1,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240122\1206993_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(1206993).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240122\1206993_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(1206993).doc""] = ""1206993_BM_5411046_ClearLLab10C_NO-MALIGNANCY"","
1206993,7311830,1206993_BM_7311830_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,44,2025.04.10,2025.04.10,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,0.1%,Blasts,11.9 ×103/μL（dilution:N/Ax）,"147,946 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1206993_7311830_AML(T).json,2025-04-10T16:55:21.3563517+08:00,69120,2025-04-10T17:05:06.0120657+08:00,1206993_7311830_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250416\1206993_7311830_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1206993_7311830_AML(T).doc,"Previous FCM results (2024.10.16): Myeloid blasts comprise approximately 0.2% of the total nucleated cells. Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.1% of total nucleated cells. These cells are positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR.",Myeloid blasts comprise approximately 0.1% of the total nucleated cells.,BM,4|4,0,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250416\1206993_7311830_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1206993_7311830_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250416\1206993_7311830_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1206993_7311830_AML(T).doc""] = ""1206993_BM_7311830_ClearLLab10C_NO-MALIGNANCY"","
1206993,5881446,1206993_BM_5881446_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,44,2024.06.17,2024.06.18,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,0.1%,Blasts,4.5 ×103/μL（dilution:N/Ax）,"122,320 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(1206993).json,2024-06-18T09:43:39.7960647+08:00,69632,2024-06-18T09:49:28.0474499+08:00,1206993_5881446_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202406\20240619\1206993_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(1206993).doc,"Previous FCM results (2024.04.15): Myeloid blasts comprise approximately 0.1% of the total nucleated cells. Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.1% of total nucleated cells. These cells are positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR.",Myeloid blasts comprise approximately 0.1% of the all nucleated cells.,BM,4|4,0,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202406\20240619\1206993_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(1206993).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202406\20240619\1206993_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(1206993).doc""] = ""1206993_BM_5881446_ClearLLab10C_NO-MALIGNANCY"","
1251678,6289483,0001251678_BM_6289483_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.05,,男,45,2024.09.12,2024.09.16,XXX,Bone marrow,MDS suspected,Acceptable,CD45/SSC,12.0%,Blasts,2.8×103/μL（dilution:N/Ax）,"81,980 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001251678_MDS.json,2024-09-12T16:54:41.5911548+08:00,72192,2024-09-16T12:29:17.8279331+08:00,0001251678_6289483_Bone marrow_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240919\0001251678_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001251678_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 5.0% of blast region analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, and HLA-DR. The MDS diagnostic flow score: 3 points. Granulocytes showed abnormal pattern for CD13/CD16 and CD13/CD11b. Monocytes showed aberrant expression of CD56. Plasmacytoid dendritic cells (pDCs) are increased.",Immunophenotyping are consistent with myelodysplastic syndrome (MDS) with increased pDCs.,BM,4|4,5,MDS,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240919\0001251678_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001251678_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240919\0001251678_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001251678_MDS.doc""] = ""0001251678_BM_6289483_ClearLLab10C_MALIGNANCY"","
278111,7066267,0000278111_PB_7066267_ClearLLab10C_MALIGNANCY,PB,Malignancy ,Acute Leukemia,0.83,,女,46,2025.02.18,2025.02.19,XXX,Other:周邊血,Leukemia suspected,Acceptable,CD45/SSC,83.3%,Blasts,17.6 ×103/μL（dilution:5x）,"98,554 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000278111_7066267_BALL(PB).json,2025-02-18T15:54:09.9071149+08:00,74752,2025-02-19T08:40:35.7410051+08:00,0000278111_7066267_Other:周邊血_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\0000278111_7066267_BALL(PB)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000278111_7066267_BALL(PB).doc,"Immunophenotyping of peripheral blood leukocytes by flow cytometry reveals a predominant abnormal B-cell population, comprising approximately 83% of all analyzed cells. These blast cells exhibit small to medium nuclear sizes, as indicated by the forward-scatter signal, and express CD19, CD20, CyCD79, CD200, and HLA-DR. Additionally, they aberrantly express CD5 and CD13 while lacking CD34 and CD38 expression. ※患者周邊血液檢體操作時間已超出採檢後24小時，可能影響分析準確度，報告判讀時請小心。",Immunophenotyping are compatible with B-lymphoblastic leukemia.,PB,4|5,-1,BALL,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\0000278111_7066267_BALL(PB)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000278111_7066267_BALL(PB).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\0000278111_7066267_BALL(PB)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000278111_7066267_BALL(PB).doc""] = ""0000278111_PB_7066267_ClearLLab10C_MALIGNANCY"","
1315087,5335525,1315087_BM_5335525_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.02,,女,48,2023-12-21,2023-12-22,XXX,Bone marrow,MDS suspected,Acceptable,CD34/SSC,2.0%,Blasts,8.7×103/μL（dilution:N/Ax）,"85,163 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1315087).json,2024-05-22T08:00:39.4149071+08:00,71168,2023-12-22T10:38:20.404+08:00,1315087_5335525_Bone marrow_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231222\1315087_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1315087).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 2.0% of all cells analyzed. These myeloblasts are positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR. These cells with aberrant expression of CD7(partial) and CD56. The MDS diagnostic flow score: 2 points. Granulocytes showed abnormal pattern for CD13/CD11b, CD13/CD16. Aberrant expression of CD56 is observed both in granulocytes and monocytes.",Myeloid blasts comprise approximately 2.0% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).,BM,4|4,5,MDS,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231222\1315087_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1315087).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231222\1315087_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1315087).doc""] = ""1315087_BM_5335525_ClearLLab10C_MALIGNANCY"","
1372490,7446447,1372490_BM_7446447_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,49,2025.05.05,2025.05.06,XXX,Bone marrow,R/O leukemia,Acceptable,CD34/SSC,0.1%,Blasts,1.8×103/μL（dilution:N/Ax）,"66,037 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1372490_7446447_MDS.json,2025-05-06T11:32:52.6539025+08:00,69632,2025-05-06T11:35:20.5380837+08:00,1372490_7446447_Bone marrow_R/O leukemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202505\20250507\1372490_7446447_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1372490_7446447_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.1% of total nucleated cells, and these myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point. ※患者骨髓檢體含有凝塊(clot)，可能影響分析結果的準確度，報告判讀時請小心。","Myeloid blasts comprise approximately 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,-1,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202505\20250507\1372490_7446447_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1372490_7446447_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202505\20250507\1372490_7446447_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1372490_7446447_MDS.doc""] = ""1372490_BM_7446447_ClearLLab10C_NO-MALIGNANCY"","
1375091,5136657,1375091_BM_5136657_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,49,2023-10-12,2023-10-13,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,0.1%,Blasts,10.4×103/μL（dilution: N/Ax）,"131,794events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1375091).json,2024-05-22T07:54:29.9328122+08:00,65536,2023-10-13T10:38:55.394+08:00,1375091_5136657_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231013\1375091_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1375091).doc,"(1) Myeloblasts account for 0.1% of total nucleated cells. (2) Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a myeloblast population that is positive for CD34, CD13, CD33, CD38, CD117, CD123 and HLA-DR. (3) Diagnostic flow score: 0 point.","Myeloid blasts comprise approximately 0.1% of the total nucleated cells, and there are no myelodysplastic syndrome (MDS)-related features.",BM,4|4,2,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231013\1375091_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1375091).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231013\1375091_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1375091).doc""] = ""1375091_BM_5136657_ClearLLab10C_NO-MALIGNANCY"","
5132489,5414330,5132489_BM_5414330_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,50,2024-01-23,2024-01-24,XXX,Bone marrow,Pancytopenia,Acceptable,CD34/SSC,0.5 %,Blasts,3.5 ×103/μL（dilution: N/A x）,"111,201 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5132489).json,2024-05-22T08:03:05.9100495+08:00,68608,2024-02-05T16:49:10.251+08:00,5132489_5414330_Bone marrow_Pancytopenia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240124\5132489_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5132489).doc,"Myeloblasts account for 0.5% of total nucleated cells. Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a myeloblast population that is positive for CD34, CD13, CD33, CD38, CD117, CD123 and HLA-DR. Diagnostic flow score: 0 point.","Myeloid blasts comprise approximately 0.5% of the total nucleated cells, and there are no myelodysplastic syndrome (MDS)-related features.",BM,4|4,2,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240124\5132489_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5132489).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240124\5132489_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5132489).doc""] = ""5132489_BM_5414330_ClearLLab10C_NO-MALIGNANCY"","
5317425,6872647,5317425_PB_6872647_ClearLLab10C_MALIGNANCY,PB,Malignancy ,"Others: MDS, MPN",0.106,,男,52,2025.01.08,2025.01.09,XXX,Other:周邊血,CML suspected,Acceptable,CD34/SSC,10.6%,Blasts,19.8×104/μL（dilution:5x）,"103,056 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5317425_6872647_CML.json,2025-01-09T15:04:30.8044187+08:00,73216,2025-01-09T15:35:06.0569348+08:00,5317425_6872647_Other:周邊血_CML suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250115\5317425_6872647_CML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5317425_6872647_CML.doc,"Immunophenotyping of peripheral blood leukocytes by flow cytometry identified myeloblasts in the blast region using CD34/SSC gating, accounting for 10% of the total nucleated cells. These cells are positive for CD13(dim), CD33, CD38, CD117, CD123, CD200, and HLA-DR. Additionally, these cells exhibit aberrant expression of CD7. Basophils, identified by CD123+/HLA-DR- gating, comprise approximately 20% of the total nucleated cells.","Myeloid blasts comprise approximately 10.6% of the total nucleated cells. Based on immunophenotyping and morphological findings, the results are suggestive of myeloproliferative neoplasms (MPN).",PB,4|4,-1,MPN,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250115\5317425_6872647_CML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5317425_6872647_CML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250115\5317425_6872647_CML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5317425_6872647_CML.doc""] = ""5317425_PB_6872647_ClearLLab10C_MALIGNANCY"","
645253,5970909,0000645253_BM_5970909_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,52,2024.07.03,2024.07.04,XXX,Bone marrow,B-ALL (post-treatment follow up),Acceptable,CD19/SSC,9.5 %,Other: B cells,18.5×103/μL（dilution:N/Ax）,"876,558 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000645253_BALL(T).json,2024-07-04T11:48:10.7631177+08:00,68608,2024-07-04T14:03:22.5387865+08:00,0000645253_5970909_Bone marrow_B-ALL (post-treatment follow up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240710\0000645253_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000645253_BALL(T).doc,"Previous FCM results (2023.09.27): B-ALL follow up, a small proportion of myeloblasts (<0.1%) were detected in the bone marrow, and no residual leukemic cells were found with flow cytometry. Immunophenotyping of bone marrow aspirate by flow cytometry showed a normal lymphoblasts (hematogones) account for 8.9% of the total nucleated cells expressing CD45 (down-regulated), CD10, CD19, CD20, CD34, and CD38. Additionally, a small proportion of myeloblasts (0.2%) were detected in the bone marrow. Minimal residual disease (MRD) for B-ALL: <0.01%","Normal progenitor B cells account for 8.9% of the total nucleated cells, and minimal residual disease is estimated to be less than 0.01%.",BM,4|4,-1,B-ALL <0.01%,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240710\0000645253_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000645253_BALL(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240710\0000645253_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000645253_BALL(T).doc""] = ""0000645253_BM_5970909_ClearLLab10C_NO-MALIGNANCY"","
645253,7037962,0000645253_BM_7037962_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,53,2025.02.12,2025.02.13,XXX,Bone marrow,B-ALL (post-treatment follow up),Acceptable,CD19/SSC,10.0 %,Other: B cells,10.2×103/μL（dilution:N/Ax）,"572,745 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000645253_7037962_BALL(T).json,2025-02-13T09:12:59.2900782+08:00,70144,2025-02-19T13:50:57.3746581+08:00,0000645253_7037962_Bone marrow_B-ALL (post-treatment follow up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\0000645253_7037962_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000645253_7037962_BALL(T).doc,"Previous FCM results (2024.07.10): B-ALL follow up, normal progenitor B cells account for 8.9% of the total nucleated cells, and minimal residual disease is estimated to be less than 0.01%. Immunophenotyping of bone marrow aspirate by flow cytometry showed a normal lymphoblasts (hematogones) account for 5.1% of the total nucleated cells expressing CD45 (down-regulated), CD10, CD19, CD20, CD34, and CD38. Additionally, a small proportion of myeloblasts (0.3%) were detected in the bone marrow. Minimal residual disease (MRD) for B-ALL: <0.01%","Normal progenitor B cells account for 5.1% of the total nucleated cells, and minimal residual disease is estimated to be less than 0.01%.",BM,4|4,-1,B-ALL MRD <0.01%,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\0000645253_7037962_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000645253_7037962_BALL(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\0000645253_7037962_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000645253_7037962_BALL(T).doc""] = ""0000645253_BM_7037962_ClearLLab10C_NO-MALIGNANCY"","
5031541,5752582,5031541_BM_5752582_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,53,2024-05-16,2024-05-17,XXX,Bone marrow,Essential thrombocythaemia,Acceptable,CD34/SSC,<0.1%,Blasts,8.1×103/μL（dilution:N/Ax）,"102,211 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5031541).json,2024-05-22T08:08:34.9216943+08:00,68608,2024-05-17T10:46:40.4354902+08:00,5031541_5752582_Bone marrow_Essential thrombocythaemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240517\5031541_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5031541).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounted for less than 0.1% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point. Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,6,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240517\5031541_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5031541).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240517\5031541_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5031541).doc""] = ""5031541_BM_5752582_ClearLLab10C_NO-MALIGNANCY"","
263078,7073338,0000263078_BM_7073338_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.013,,女,54,2025.02.19,2025.02.20,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,1.3%,Blasts,4.3×103/μL（dilution:N/Ax）,"116,536 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000263078_7073338_MDS.json,2025-02-19T16:55:27.9922887+08:00,72704,2025-02-20T08:57:59.6756044+08:00,0000263078_7073338_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250227\0000263078_7073338_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000263078_7073338_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry identified myeloblasts in the blast region using CD34/SSC gating, accounting for 1.3% of the total nucleated cells.   These myeloblasts are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. Additionally, these cells exhibit aberrant expression of CD56. The MDS diagnostic flow score: 3 points. Granulocytes exhibit an abnormal pattern for CD13/CD16 and CD13/CD11b, along with decreased SSC. Monocytes display aberrant expression of CD56.","Myeloid blasts comprise approximately 1.3% of the total nucleated cells, and   immunophenotyping are compatible with myelodysplastic syndromes (MDS).",BM,4|4,-1,MDS,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250227\0000263078_7073338_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000263078_7073338_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250227\0000263078_7073338_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000263078_7073338_MDS.doc""] = ""0000263078_BM_7073338_ClearLLab10C_MALIGNANCY"","
345633,7307802,0000345633_BM_7307802_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,54,2025.04.09,2025.04.10,XXX,Bone marrow,B-ALL (post-treatment follow up),Acceptable,CD19/SSC,7.9%,Other: B cells,16.8×103/μL（dilution:N/Ax）,"811,874 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000345633_BALL(T).json,2025-04-10T08:47:46.19297+08:00,69632,2025-04-10T09:04:39.5436417+08:00,0000345633_7307802_Bone marrow_B-ALL (post-treatment follow up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250416\0000345633_7307802_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000345633_BALL(T).doc,"Previous FCM results (2024.07.26): Normal progenitor B cells account for 0.3% of the total nucleated cells, and minimal residual disease is less than 0.01%. Immunophenotyping of bone marrow aspirate by flow cytometry showed a normal lymphoblasts (hematogones) account for 6.2% of the total nucleated cells expressing CD45 (down-regulated), CD10, CD19, CD20, CD38, and CD200. Additionally, a small proportion of myeloblasts (0.2%) were detected in the bone marrow. Minimal residual disease (MRD) for B-ALL: <0.01%","Normal progenitor B cells account for 6.2% of the total nucleated cells, and minimal residual disease is less than 0.01%.",BM,4|4,-1,B-AMM MRD<0.01%,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250416\0000345633_7307802_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000345633_BALL(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250416\0000345633_7307802_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000345633_BALL(T).doc""] = ""0000345633_BM_7307802_ClearLLab10C_NO-MALIGNANCY"","
5066943,5175700,5066943_BM_5175700_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,54,2023-10-30,2023-10-31,XXX,Bone marrow,Essential thrombocythemia suspected,Acceptable,CD34/SSC,0.3%,Blasts,5.2×103/μL（dilution:N/Ax）,"106,681 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5066943).json,2024-05-22T07:55:59.5754749+08:00,65024,2023-10-31T10:07:23.296+08:00,5066943_5175700_Bone marrow_Essential thrombocythemia suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231030\5066943_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5066943).doc,"(1) Myeloblasts account for 0.3% of total nucleated cells. (2) Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a myeloblast population that is positive for CD34, CD13, CD33, CD38, CD117, CD123 and HLA-DR. (3) Diagnostic flow score: 1 point.","Myeloid blasts comprise approximately 0.3% of the total nucleated cells, and there are no myelodysplastic syndrome (MDS)-related features.",BM,4|4,2,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231030\5066943_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5066943).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231030\5066943_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5066943).doc""] = ""5066943_BM_5175700_ClearLLab10C_NO-MALIGNANCY"","
222824,7153182,0000222824_BM_7153182_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.44,,男,55,2025.03.07,2024.03.10,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,44.7%,Blasts,6.7×103/μL（dilution:N/Ax）,"96,635 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000222824_7153182_AML.json,2025-03-10T11:02:09.319609+08:00,76288,2025-03-10T11:11:55.9656338+08:00,0000222824_7153182_Bone marrow_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250312\0000222824_7153182_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000222824_7153182_AML.doc,"Flow cytometric immunophenotyping of bone marrow aspirate reveals a predominant myeloblast population, comprising approximately 44% of the total nucleated cells. These cells are positive for MPO, CD34, CD13, CD33 (bright), CD38, CD117 (bright), CD123, and HLA-DR (bright). They are negative for CD10, CD19, CyCD3, and CyCD79a. The myeloblast population displays aberrant expression of CD7. Granulocytes comprise approximately 41% of the nucleated bone marrow cells.",Immunophenotyping are compatible with acute myeloid leukemia (AML) with maturation.,BM,4|5,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250312\0000222824_7153182_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000222824_7153182_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250312\0000222824_7153182_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000222824_7153182_AML.doc""] = ""0000222824_BM_7153182_ClearLLab10C_MALIGNANCY"","
1433478,6601642,0001433478_BM_6601642_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,55,2024-11-18,2024-11-19,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,0.1%,Blasts,2.6×103/μL（dilution:N/Ax）,"103,835 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0001433478).json,2024-11-19T12:04:46.0242271+08:00,68096,2024-11-20T07:59:30.5688359+08:00,0001433478_6601642_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241120\0001433478_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0001433478).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.1% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 0 point. ※患者骨髓檢體送檢已超出採檢後24小時，可能影響分析準確度，報告判讀時請小心。","Myeloid blasts comprise approximately 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,-1,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241120\0001433478_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0001433478).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241120\0001433478_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0001433478).doc""] = ""0001433478_BM_6601642_ClearLLab10C_NO-MALIGNANCY"","
2192034,5314402,2192034_BM_5314402_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.51,,女,57,2023-12-14,2023-12-15,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD45/SSC,51.1%,Blasts,5.1×103/μL（dilution:N/Ax）,"112,089 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(2192034).json,2024-05-22T07:59:11.8618338+08:00,71680,2023-12-15T09:20:45.595+08:00,2192034_5314402_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231215\2192034_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(2192034).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry shows a predominant myeloblast population, comprising approximately 51% of the total nucleated cells. These cells are positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR. They have an intermediate to large size (based on FSC signal). Additionally, they displayed aberrant expression of CD56(partial).",Myeloid blasts comprise approximately 51% of all nucleated cells in the bone marrow.,BM,4|4,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231215\2192034_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(2192034).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231215\2192034_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(2192034).doc""] = ""2192034_BM_5314402_ClearLLab10C_MALIGNANCY"","
5097547,6967273,5097547_BM_6967273_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.3,,女,57,2025.01.27,2025.01.27,XXX,Bone marrow,Acute leukemia suspected,Acceptable,CD45/SSC,30.0%,Blasts,13.2×103/μL（dilution:N/Ax）,"56,939 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5097547_6967273_AML.json,2025-01-27T15:54:26.7176734+08:00,74752,2025-01-27T16:26:17.2846655+08:00,5097547_6967273_Bone marrow_Acute leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250131\5097547_6967273_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5097547_6967273_AML.doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry reveals a myeloblast population, accounting for approximately 30% of the total nucleated cells. These cells are positive for MPO, CD34 (bright), CD13, CD33, CD38, CD117 (bright), CD123, and HLA-DR, but negative for CD7, CD10, CD19, CyCD3, and CyCD79a. Normoblasts comprise approximately 60% of the nucleated bone marrow cells.","Immunophenotyping is compatible with acute myeloid leukemia (AML), and normoblasts are predominantly increased.",BM,4|5,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250131\5097547_6967273_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5097547_6967273_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250131\5097547_6967273_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5097547_6967273_AML.doc""] = ""5097547_BM_6967273_ClearLLab10C_MALIGNANCY"","
2192034,5266228,2192034_BM_5266228_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.25,,女,57,2023-11-29,2023-11-30,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,25.2%,Blasts,3.3×103/μL（dilution:N/Ax）,"108,408 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(2192034).json,2024-05-22T07:58:02.6494042+08:00,67584,2023-12-05T15:43:34.597+08:00,2192034_5266228_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231130\2192034_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(2192034).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry shows a predominant myeloblast population, comprising approximately 25% of the total nucleated cells. These cells are positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR (bright). They have an intermediate to large size (based on FSC signal). Monocytic components decrease as compared to the previous finding.",Myeloid blasts comprise approximately 25% of all nucleated cells in the bone marrow.,BM,4|4,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231130\2192034_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(2192034).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231130\2192034_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(2192034).doc""] = ""2192034_BM_5266228_ClearLLab10C_MALIGNANCY"","
285136,5158349,0285136_BM_5158349_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.093,,女,58,2023-10-23,2023-10-24,XXX,Bone marrow,MDS-suspected,Acceptable,CD34/SSC,9.3%,Blasts,15×103/μL（dilution: 3 x）,"147,028 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0285136).json,2024-05-22T07:55:31.9346539+08:00,70144,2023-10-24T14:49:29.366+08:00,0285136_5158349_Bone marrow_MDS-suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231024\0285136_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0285136).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 9.3% of total nucleated cells. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, HLA-DR, and aberrant expression of CD5(partial) and CD56. (2) MDS diagnostic flow score: 4 points. (3) Granulocytes showed abnormal pattern for CD13/CD16, CD13/CD11b and decreased SSC. (4) Monocytes showed aberrant expression of CD56, and shift toward immature distribution of maturation stages.",Myeloid blasts comprise approximately 9.3% of total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS). Please correlate with cytogenetic testing for .,BM,4|4,5,MDS,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231024\0285136_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0285136).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231024\0285136_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0285136).doc""] = ""0285136_BM_5158349_ClearLLab10C_MALIGNANCY"","
176271,6014264,0176271_BM_6014264_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.084,,女,58,2024.07.11,2024.07.12,XXX,Bone marrow,B-ALL (post-treatment follow-up),Suboptimal (reason: clot     ),CD45/SSC,8.4%,Blasts,6.8 ×103/μL（dilution:N/Ax）,"143,880 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0176271_BALL(T).json,2024-07-11T16:59:15.7449441+08:00,71168,2024-07-17T11:45:21.461654+08:00,0176271_6014264_Bone marrow_B-ALL (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240717\0176271_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0176271_BALL(T).doc,"Previous FCM results(2023.09.07): post-treatment follow-up for B-ALL, no residual leukemic cells were found with flow cytometry. Immunophenotyping of the bone marrow aspirate by flow cytometry reveals an abnormal B cell population (about 8% of all the cells analyzed). These cells have small nuclear size (based on forward-scatter signal) and show expression of CD34, CD10(bright), CD19, CD38, CD200, and HLA-DR. Furthermore, they also show aberrant expression of CD5, CD13, CD33 and CD123.","Immunophenotyping are indicative of residual disease, with 8.4% of leukemic cells detected in this patient with precursor B-acute lymphoblastic leukemia following chemotherapy.",BM,4|4,-1,B-ALL MRD+,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240717\0176271_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0176271_BALL(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240717\0176271_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0176271_BALL(T).doc""] = ""0176271_BM_6014264_ClearLLab10C_MALIGNANCY"","
1163749,7112506,1163749_BM_7112506_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.051,,男,58,2025.02.27,2025.02.27,XXX,Bone marrow,"Aplastic anemia, MDS suspected",Acceptable,CD45/SSC,5.1%,Blasts,6.4×103/μL（dilution:N/Ax）,"253,039 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1163749_7112506_MDS.json,2025-02-27T15:47:01.0307593+08:00,71680,2025-02-27T16:07:14.9343975+08:00,"1163749_7112506_Bone marrow_Aplastic anemia, MDS suspected_4|4.json",\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250227\1163749_7112506_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1163749_7112506_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry revealed an abnormal population comprising approximately 5% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, CD200, and HLA-DR. Additionally, these cells exhibit aberrant expression of CD11b (dim). The MDS diagnostic flow score: 2 points. Granulocytes exhibit an abnormal pattern for CD13/CD16 and CD13/CD11b. Decreased percentage of monocytes, with a predominant increase in normoblasts (75%).","Myeloid blasts comprise approximately 5.1% of the total nucleated cells, and   immunophenotyping are compatible with myelodysplastic syndromes (MDS).",BM,4|4,5,MDS,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250227\1163749_7112506_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1163749_7112506_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250227\1163749_7112506_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1163749_7112506_MDS.doc""] = ""1163749_BM_7112506_ClearLLab10C_MALIGNANCY"","
5184898,5639527,5184898_BM_5639527_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,58,2024-04-17,2024-04-17,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,<0.1%,Blasts,17.5×103/μL（dilution:N/Ax）,"102,015events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5184898).json,2024-05-22T08:06:49.9479472+08:00,67072,2024-04-17T17:13:40.934+08:00,5184898_5639527_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240418\5184898_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5184898).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounted for less than 0.1% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,7,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240418\5184898_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5184898).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240418\5184898_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(5184898).doc""] = ""5184898_BM_5639527_ClearLLab10C_NO-MALIGNANCY"","
176271,7412025,0176271_BM_7412025_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.04,,女,59,2025.04.29,2025.04.30,XXX,Bone marrow,B-ALL (post-treatment follow-up),Acceptable,CD34/SSC,4.0%,Blasts,8.9 ×103/μL（dilution:N/Ax）,"137,688 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0176271_7412025_BALL(T).json,2025-04-29T17:27:40.6304665+08:00,73728,2025-04-30T09:20:42.4602245+08:00,0176271_7412025_Bone marrow_B-ALL (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250430\0176271_7412025_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0176271_7412025_BALL(T).doc,"Previous FCM results (2024.07.17): Immunophenotyping are indicative of residual disease, with 8.4% of leukemic cells detected in this patient with precursor B-acute lymphoblastic leukemia following chemotherapy. Immunophenotyping of the bone marrow aspirate by flow cytometry reveals an abnormal B-cell population identified by CD34/SSC gating in the blast region, accounting for 4.0% of total nucleated cells. These cells are characterized by small nuclear size (based on forward scatter) and exhibit bright expression of CD34, CD10, CD200, and HLA-DR, as well as dim expression of CD19 and CD38. In addition, they show aberrant expression of CD5, CD13, CD33, and CD123.","Immunophenotyping are indicative of residual disease, with 4.0% of leukemic cells detected in this patient with precursor B-acute lymphoblastic leukemia following chemotherapy.",BM,4|4,-1,B-ALL,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250430\0176271_7412025_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0176271_7412025_BALL(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250430\0176271_7412025_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0176271_7412025_BALL(T).doc""] = ""0176271_BM_7412025_ClearLLab10C_MALIGNANCY"","
285136,6134243,0000285136_BM_6134243_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.028,,女,59,2024.08.08,2024.08.09,XXX,Bone marrow,MDS (post-treatment follow-up),Acceptable,CD34/SSC,2.8%,Blasts,2.3×103/μL（dilution:N/Ax）,"105,087 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000285136_MDS.json,2024-08-09T11:07:45.7073123+08:00,71680,2024-08-09T13:48:20.982254+08:00,0000285136_6134243_Bone marrow_MDS (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202408\20240814\0000285136_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000285136_MDS.doc,"Previous FCM results (2023.10.24): Myeloid blasts comprise approximately 9.3% of total nucleated cells. Immunophenotyping are consistent with MDS. Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 2.8% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, and HLA-DR. These cells also show aberrant expression of CD5 and CD56. The MDS diagnostic flow score: 2 points. Granulocytes showed abnormal pattern for CD15/CD10, CD13/CD11b, CD13/CD16, and decreased SSC. Monocytes showed aberrant expression of CD56.",Myeloid blasts comprise approximately 2.8% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).,BM,4|4,0,MDS,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202408\20240814\0000285136_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000285136_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202408\20240814\0000285136_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000285136_MDS.doc""] = ""0000285136_BM_6134243_ClearLLab10C_MALIGNANCY"","
332899,6877662,0000332899_BM_6877662_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.024,,女,59,2025.01.08,2025.01.09,XXX,Bone marrow,MDS suspected,Acceptable,CD34/SSC,2.4%,Blasts,2.2×103/μL（dilution:N/Ax）,"138,740 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000332899_6877662_MDS.json,2025-01-09T15:07:02.4237909+08:00,72704,2025-01-09T15:55:04.2422809+08:00,0000332899_6877662_Bone marrow_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250115\0000332899_6877662_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000332899_6877662_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry identified myeloblasts in the blast region using CD34/SSC gating, accounting for 2.4% of the total nucleated cells.   These myeloblasts are positive for CD13, CD33(dim), CD38, CD117, CD123, CD200, and HLA-DR. Additionally, these cells exhibit aberrant expression of CD7 and CD56. The MDS diagnostic flow score: 2 points. Granulocytes exhibited an abnormal pattern for CD13/CD16. Monocytes exhibited aberrant expression of CD56.","Myeloid blasts comprise approximately 2.4% of the total nucleated cells, and   immunophenotyping are compatible with myelodysplastic syndromes (MDS).",BM,4|4,-1,MDS,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250115\0000332899_6877662_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000332899_6877662_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250115\0000332899_6877662_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000332899_6877662_MDS.doc""] = ""0000332899_BM_6877662_ClearLLab10C_MALIGNANCY"","
2167503,7232903,0002167503_BM_7232903_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.94,,男,60,2025.03.24,2025.03.25,XXX,Bone marrow,AML suspected,Acceptable,CD45/SSC,93.9%,Blasts,14.1 ×103/μL（dilution:10x）,"96,542 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002212028_AMoL.json,2025-03-25T15:56:03.1246164+08:00,76288,2025-03-25T16:11:48.1691244+08:00,0002167503_7232903_Bone marrow_AML suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250326\0002167503_7232903_AMoL\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002212028_AMoL.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant blast cells population near the granulocyte gate region, comprising approximately 94% of the total nucleated cells. These cells are positive for MPO (partial), CD4, CD11b, CD13, CD14, CD33, CD38, CD64 (bright), CD123, and HLA-DR；additionally, they are negative for CD34, CD7, CD10, CD19, CyCD79a, CyCD3, and CD117. These cells have intermediate to large size (based on forward-scatter signal), and show aberrant expression of CD15 and CD56.","Immunophenotyping, together the presence of 85% immature monocytes in the bone marrow, is most consistent with acute monocytic leukemia. Please correlate these findings with the genetic results.",BM,4|5,-1,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250326\0002167503_7232903_AMoL\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002212028_AMoL.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250326\0002167503_7232903_AMoL\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002212028_AMoL.doc""] = ""0002167503_BM_7232903_ClearLLab10C_MALIGNANCY"","
301002,5617224,0301002_BM_5617224_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.67,,男,60,2024-04-11,2024-04-12,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD45/SSC,67.1%,Blasts,16.2×103/μL（dilution: N/A x）,"97,335 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0301002).json,2024-05-22T08:06:04.9063394+08:00,73728,2024-04-12T11:26:37.0650202+08:00,0301002_5617224_Bone marrow_AML (post-treatment follow-up)_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240412\0301002_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0301002).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant myeloblast population, comprising approximately 67% of the total nucleated cells. These cells are positive for CD34, MPO, CD11b(partial), CD13, CD33, CD38, CD64(partial), CD117, CD123, CD200, and HLA-DR. Additionally, they are negative for CD19, CyCD79a and CyCD3. Myeloblasts show aberrant expression of CD7(partial).",Relapse of acute myeloid leukemia (AML).,BM,4|5,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240412\0301002_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0301002).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240412\0301002_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0301002).doc""] = ""0301002_BM_5617224_ClearLLab10C_MALIGNANCY"","
233038,5471333,0233038_BM_5471333_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,60,2024-02-15,2024-02-15,XXX,Bone marrow,MDS suspected,Acceptable,CD34/SSC,<0.1%,Blasts,6.3×103/μL（dilution:N/Ax）,"118,495 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MDS(0233038).json,2024-05-22T08:03:46.4414722+08:00,67072,2024-02-15T13:41:01.238+08:00,0233038_5471333_Bone marrow_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240215\0233038_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MDS(0233038).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable. Hematogones account for approximately 0.2% of the total nucleated cells expressing CD45(down-regulated), CD34 (partial), CD10 (bright), CD19, and CD38(bright). MDS diagnostic flow score: 1 point.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,1,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240215\0233038_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MDS(0233038).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240215\0233038_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MDS(0233038).doc""] = ""0233038_BM_5471333_ClearLLab10C_NO-MALIGNANCY"","
1448486,5630804,1448486_BM_5630804_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.83,,男,61,2024-04-15,2024-04-16,XXX,Bone marrow,AML suspected,Acceptable,CD45/SSC,83.4%,Blasts,14.8×103/μL（dilution: 10 x）,"100,186 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(1448486).json,2024-05-22T08:06:15.8667306+08:00,74240,2024-04-16T09:50:25.7692505+08:00,1448486_5630804_Bone marrow_AML suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240415\1448486_AML(MO)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(1448486).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant blast population, comprising approximately 83% of the total nucleated cells. These cells are positive for CD34(partial), MPO(dim), CD11b, CD13, CD14, CD33(bright), CD38, CD64, CD117(partial), CD123, and HLA-DR. Additionally, they are negative for CD19, CyCD79a and CyCD3. Blasts show aberrant expression of CD56.","Immunophenotyping, together with morphological findings in bone marrow, are consistent with acute monoblastic leukemia.",BM,4|5,-1,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240415\1448486_AML(MO)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(1448486).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240415\1448486_AML(MO)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(1448486).doc""] = ""1448486_BM_5630804_ClearLLab10C_MALIGNANCY"","
5137425,5483974,5137425_BM_5483974_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.6,,女,61,2024-02-19,2024-02-20,XXX,Bone marrow,Multiple myeloma (post-treatment follow-up),Acceptable,CD34/SSC,60.7%,Blasts,6.4 ×103/μL（dilution:N/Ax）,"74,701 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-BALL(5137425).json,2024-05-22T08:04:25.1028293+08:00,73728,2024-02-20T12:16:56.099+08:00,5137425_5483974_Bone marrow_Multiple myeloma (post-treatment follow-up)_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240220\5137425_BALL\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-BALL(5137425).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry reveals a population of lymphoid cells (12.2%) with normal expression and no signs of surface light-chain restriction. Among the cells analyzed using CD38/CD138 gating, plasma cells account for approximately 0.1%, and they do not display any abnormal expression or evidence of cytoplasmic light-chain restriction. In addition, there is predominant an abnormal B cell population (about 60% of all the cells analyzed). These cells have small to large nuclear size (based on forward-scatter signal) and show expression of CD34(bright), CD10, CD19, CD38, CyCD79a, CD200, and HLA-DR. Furthermore, they also show aberrant expression of CD13, CD33 and CD123.",Immunophenotyping are consistent with precursor B-acute lymphoblastic leukemia (B-ALL).,BM,4|5,-1,B-ALL,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240220\5137425_BALL\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-BALL(5137425).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240220\5137425_BALL\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-BALL(5137425).doc""] = ""5137425_BM_5483974_ClearLLab10C_MALIGNANCY"","
885609,7203862,0000885609_BM_7203862_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.57,,男,61,2025.03.18,2025.03.18,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,57.7%,Blasts,2.1×103/μL（dilution:N/Ax）,"91,032 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000885609_7203862_AML.json,2025-03-18T16:45:43.9441651+08:00,76800,2025-03-18T17:00:46.6823255+08:00,0000885609_7203862_Bone marrow_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250319\0000885609_7203862_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000885609_7203862_AML.doc,"Flow cytometric immunophenotyping of bone marrow aspirate reveals a predominant myeloblast population, comprising approximately 57% of the total nucleated cells. These cells are positive for MPO, CD34 (bright), CD13, CD33, CD38 (bright), CD117 (bright), CD123, and HLA-DR (bright). They are negative for CD10, CyCD3, and CyCD79a. The myeloblast population exhibits aberrant expression of CD7, CD19, and CD56. Granulocytes comprise approximately 12% of the nucleated bone marrow cells.",Immunophenotyping are compatible with acute myeloid leukemia (AML).,BM,4|5,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250319\0000885609_7203862_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000885609_7203862_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250319\0000885609_7203862_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000885609_7203862_AML.doc""] = ""0000885609_BM_7203862_ClearLLab10C_MALIGNANCY"","
301002,5511289,0301002_BM_5511289_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.018,,男,61,2024-02-29,2024-03-01,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,1.8%,Blasts,5.7×103/μL（dilution: N/A x）,"99,783 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0301002).json,2024-05-22T08:04:31.9930712+08:00,70144,2024-03-01T08:51:47.055+08:00,0301002_5511289_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240229\0301002_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0301002).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 1.8% of total nucleated cells. These cells exhibited expression for CD7 (partial), CD13, CD33, CD38, CD117, CD123, and HLA-DR.",Myeloid blasts comprise approximately 1.8% of all nucleated cells in bone marrow.,BM,4|4,3,AML MRD+,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240229\0301002_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0301002).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240229\0301002_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0301002).doc""] = ""0301002_BM_5511289_ClearLLab10C_MALIGNANCY"","
889039,6152842,0000889039_BM_6152842_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.96,,女,63,2024.08.12,2024.08.13,XXX,Bone marrow,AML suspected,Acceptable,CD45/SSC,96.5%,Leukemic cells,18.9 ×103/μL（dilution:5x）,"81,430 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_000889039_AML(APL mimic).json,2024-08-13T11:23:32.2185672+08:00,74240,2024-08-14T12:24:27.7177488+08:00,0000889039_6152842_Bone marrow_AML suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202408\20240814\0000889039_AML(APL mimic)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_000889039_AML(APL mimic).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant leukemic cell population, comprising approximately 96% of the total nucleated cells. These cells are positive for CD33, CD38, CD117, CD123, and MPO. Additionally, they are negative for CD34, CD7, CD10, CD13, CD19, CyCD79a, CyCD3, and HLA-DR. These cells have intermediate granularity (based on side-scatter signal), and show aberrant expression of CD56.","Immunophenotyping, together with morphological findings in bone marrow, are consistent with acute myeloid leukemia (AML). These findings are like acute promyelocytic leukemia but favor AML with mutated NPM1. Please correlate these findings with the genetic results.",BM,4|5,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202408\20240814\0000889039_AML(APL mimic)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_000889039_AML(APL mimic).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202408\20240814\0000889039_AML(APL mimic)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_000889039_AML(APL mimic).doc""] = ""0000889039_BM_6152842_ClearLLab10C_MALIGNANCY"","
68833,6393524,0000068833_BM_6393524_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.96,,男,63,2024.10.04,2024.10.04,XXX,Bone marrow,Acute leukemia suspected.,Acceptable,CD45/SSC,96.1%,Blasts,19.8×103/μL（dilution:3x）,"111,740events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_AML.json,2024-10-04T14:32:56.8512064+08:00,70144,2024-10-04T15:00:02.8974848+08:00,0000068833_6393524_Bone marrow_Acute leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241009\0000068833_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_AML.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant myeloblast population, comprising approximately 96% of the total nucleated cells. These cells are positive for CD34, MPO (bright), CD13, CD33, CD38, CD117, CD123, and HLA-DR. Additionally, they are negative for CD7, CD10, CD19, CyCD3 and CyCD79a.",Immunophenotyping are compatible with acute myeloid leukemia without maturation.,BM,4|5,4,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241009\0000068833_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241009\0000068833_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_AML.doc""] = ""0000068833_BM_6393524_ClearLLab10C_MALIGNANCY"","
5202890,6633401,5202890_BM_6633401_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.5,,男,63,2024.11.21,2024.11.22,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,50.4%,Leukemic cells,2.4×103/μL（dilution : N/A x）,"48,143 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5202890_AMML .json,2024-11-26T17:10:51.420465+08:00,33514,2024-11-27T09:33:51.4260977+08:00,5202890_6633401_Bone marrow_Leukemia suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\5202890_AMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5202890_AMML .docx,"Immunophenotyping of bone marrow aspirate by flow cytometry shows a predominant blast （about 50%） on the monocytes region that is positive for MPO, CD4, CD11b, CD13, CD15, CD33, CD38, CD64, CD123, HLA-DR, and partial positivity for CD34. These blasts are negative for CyCD3, CyCD79a, CD7, CD19, CD10, and CD117. Granulocytes account approximately about >20%.",Immunophenotyping are compatible with acute myelomonocytic leukemia.,BM,4|4,-1,AML,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\5202890_AMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5202890_AMML .docx,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\5202890_AMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5202890_AMML .docx""] = ""5202890_BM_6633401_ClearLLab10C_MALIGNANCY"","
68833,6691562,0000068833_BM_6691562_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,63,2024.12.02,2024.12.03,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,0.2%,Blasts,10.2 ×103/μL（dilution: N/Ax）,"122,436 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_AML(T).json,2024-12-03T15:02:29.0857758+08:00,68096,2024-12-03T15:02:29.1867961+08:00,0000068833_6691562_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241204\0000068833_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_AML(T).doc,"Previous FCM results (2024.10.30): acute myeloid leukemia with monocytic component. Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a small number of normal myeloblasts population (0.2%) that is positive for CD34, CD7(partial), CD13, CD33, CD38, CD117, CD123, and HLA-DR.",No abnormal immunophenotypes associated with AML are found with flow cytometry.,BM,4|4,-1,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241204\0000068833_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241204\0000068833_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_AML(T).doc""] = ""0000068833_BM_6691562_ClearLLab10C_NO-MALIGNANCY"","
2228358,7376742,0002228358_BM_7376742_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.024,,男,64,2025.03.26,2025.03.27,XXX,Bone marrow,Refractory cytopenia with multilineage dysplasia,Acceptable,CD34/CD45,2.4%,Blasts,16.7×103/μL （dilution:N/Ax）,"521,435 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002228358_7376742_MDS.json,2025-04-22T16:30:09.8986579+08:00,74240,2025-04-22T16:51:10.0486945+08:00,0002228358_7376742_Bone marrow_Refractory cytopenia with multilineage dysplasia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250423\0002228358_7376742_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002228358_7376742_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 2.4% of total nucleated cells. These myeloblasts are positive for CD13, CD33 (bright), CD34, CD38, CD117 (bright), CD123 (bright), and HLA-DR. The MDS diagnostic flow score: 4 points. Granulocytes exhibited an abnormal pattern for CD13/CD16 and CD13/CD11b, along with decreased SSC. Monocytes: decreased (0.1%). A predominant population of normoblasts, accounting for approximately 83% of the total nucleated cells.","Myeloid blasts comprise approximately 2.4% of the total nucleated cells, with an increased number of normoblasts. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).",BM,4|4,-1,MDS,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250423\0002228358_7376742_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002228358_7376742_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250423\0002228358_7376742_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002228358_7376742_MDS.doc""] = ""0002228358_BM_7376742_ClearLLab10C_MALIGNANCY"","
68833,7108343,0000068833_BM_7108343_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,64,2025.02.26,2025.02.27,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,0.1%,Blasts,7.4 ×103/μL（dilution: N/Ax）,"117,910 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_7108343_AML(T).json,2025-02-27T12:03:12.1353114+08:00,67584,2025-02-27T13:51:34.117931+08:00,0000068833_7108343_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250227\0000068833_7108343_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_7108343_AML(T).doc,"Previous FCM results (2024.12.04): No abnormal immunophenotypes associated with AML are found with flow cytometry. Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a small number of normal myeloblasts population (0.1%) that is positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR.",No abnormal immunophenotypes associated with AML are found with flow cytometry.,BM,4|4,-1,Non-malignant,21-65y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250227\0000068833_7108343_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_7108343_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250227\0000068833_7108343_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000068833_7108343_AML(T).doc""] = ""0000068833_BM_7108343_ClearLLab10C_NO-MALIGNANCY"","
513617,6910802,0000513617_BM_6910802_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Chronic Leukemia,0.12,,女,65,2025.01.14,2025.01.17,XXX,Bone marrow,MDS/MPN suspected,Acceptable,CD34/SSC,12.5%,Blasts,12.8×103/μL（dilution : N/A x）,"110,276 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000513617_6910802_CMML.json,2025-01-17T13:33:45.2003483+08:00,73216,2025-01-17T17:26:09.4749832+08:00,0000513617_6910802_Bone marrow_MDS/MPN suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0000513617_6910802_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000513617_6910802_CMML.doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed an abnormal population comprising approximately 12% of all cells analyzed. These blasts are positive for CD34, CD4, CD11b (dim), CD13 (bright), CD14 (dim), CD33, CD64, and HLA-DR (dim). Additionally, these cells exhibit aberrant expression of CD7, CD15, and CD56. Myelomonocytic cells (include granulocytes and monocytes) comprise approximately 80% of total nucleated cells. these cells are positive for CD4, CD11b (dim), CD13, CD14 (dim), CD15 (dim), CD33 (bright), CD38, CD64, and CD123(dim). The MDS diagnostic flow score: 3 points. 2025.1.13 CBC&DC result: WBC count:46,070/μL；monocytes:48%, blasts:2% (by manual DC). ※患者骨髓檢體操作時間已超出採檢後24小時，可能影響分析準確度，報告判讀時請小心。","Immunophenotyping, together with morphological findings, favors chronic myelomonocytic leukemia. Please correlation with the pathological report for further .",BM,4|4,-1,CML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0000513617_6910802_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000513617_6910802_CMML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0000513617_6910802_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000513617_6910802_CMML.doc""] = ""0000513617_BM_6910802_ClearLLab10C_MALIGNANCY"","
954875,7004882,0954875_BM_7004882_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,65,2025.02.06,2025.02.07,XXX,Bone marrow,Polyneuropathy,Acceptable,CD34/SSC,0.1%,Blasts,9.0×103/μL（dilution:N/Ax）,"107,840 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-09548757004882_NBM.json,2025-02-07T12:29:51.1667367+08:00,69632,2025-02-07T13:56:02.5232164+08:00,0954875_7004882_Bone marrow_Polyneuropathy_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250212\0954875_7004882_NBM\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-09548757004882_NBM.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 8.2% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 1.3% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Another small cell population, identified as myeloblasts by gating on CD34/SSC in the blast region, comprises 0.1% of the total nucleated cells. These cells are positive for CD13, CD33, CD34, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point. Monocytes display aberrant expression of CD56.",No abnormal immunophenotypes are found with flow cytometry.,BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250212\0954875_7004882_NBM\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-09548757004882_NBM.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250212\0954875_7004882_NBM\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-09548757004882_NBM.doc""] = ""0954875_BM_7004882_ClearLLab10C_NO-MALIGNANCY"","
5159645,7452046,5159645_BM_7452046_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.2,,女,66,2025.05.06,2025.05.06,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD45/SSC,20.3%,Blasts,7.2×103/μL（dilution: N/A x）,"129,060 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5159645_7452046_AML(T).json,2025-05-06T16:36:28.0502225+08:00,71680,2025-05-06T16:43:27.2426418+08:00,5159645_7452046_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202505\20250507\5159645_7452046_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5159645_7452046_AML(T).doc,"Previous FCM results (2024.05.01): A small proportion of abnormal myeloblasts (approximately 0.2%) were detected in the bone marrow. Flow cytometric immunophenotyping of bone marrow aspirate reveals a myeloblast population comprising approximately 20% of total nucleated cells, which expresses CD13, CD33, CD34, CD38, CD117, CD123, CD200, and HLA-DR, with aberrant expression of CD7 and CD56.","Immunophenotyping are compatible with acute myeloid leukemia, relapse.",BM,4|4,-1,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202505\20250507\5159645_7452046_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5159645_7452046_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202505\20250507\5159645_7452046_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5159645_7452046_AML(T).doc""] = ""5159645_BM_7452046_ClearLLab10C_MALIGNANCY"","
729581,5640928,0729581_BM_5640928_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,66,2024-04-17,2024-04-18,XXX,Bone marrow,Anemia,Acceptable,CD34/SSC,0.1%,Blasts,12.5×103/μL（dilution:N/Ax）,"105,546 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0729581).json,2024-05-22T08:06:38.9075531+08:00,67584,2024-04-18T09:14:53.372+08:00,0729581_5640928_Bone marrow_Anemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240418\0729581_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0729581).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.1% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 0 point.","Myeloid blasts comprise approximately 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,7,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240418\0729581_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0729581).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240418\0729581_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0729581).doc""] = ""0729581_BM_5640928_ClearLLab10C_NO-MALIGNANCY"","
780102,5189442,0780102_BM_5189442_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.48,,男,67,2023-11-03,2023-11-06,XXX,Bone marrow,AML suspected,Acceptable,CD34/SSC,47.6%,Blasts,10.7×103/μL（dilution:10x）,"164,410 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0780102).json,2024-05-22T07:56:22.2261478+08:00,69632,2023-11-07T17:02:01.731+08:00,0780102_5189442_Bone marrow_AML suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231107\0780102_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0780102).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant myeloblast population, comprising approximately 48% of the total nucleated cells. These cells are positive for CD34, CD13, CD33, CD38 (partial), CD117, CD123, and HLA-DR. Additionally, they are negative for MPO, CD7, CD19, CyCD79a, CyCD3, and CD200.","Immunophenotypes are consistent with acute myeloid leukemia with maturation, please correlate these findings with cytogenetic/genetics results.",BM,4|5,4,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231107\0780102_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0780102).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231107\0780102_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0780102).doc""] = ""0780102_BM_5189442_ClearLLab10C_MALIGNANCY"","
313866,6601622,0000313866_BM_6601622_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.033,,男,67,2024.11.18,2024.11.19,XXX,Bone marrow,MDS suspected,Acceptable,CD34/SSC,3.3%,Blasts,6.9×103/μL（dilution:N/Ax）,"120,881 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000313866_MDS.json,2024-11-19T13:42:42.4157732+08:00,72704,2024-11-20T08:12:54.290808+08:00,0000313866_6601622_Bone marrow_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241120\0000313866_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000313866_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 3.3% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, CD200, and HLA-DR. These cells also show aberrant expression of CD7. The MDS diagnostic flow score: 4 points. Granulocytes showed abnormal pattern for CD13/CD16 and CD13/CD11b, and decreased SSC.",Myeloid blasts comprise approximately 3.3% of the total nucleated cells. Immunophenotyping are compatible with myelodysplastic syndromes (MDS).,BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241120\0000313866_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000313866_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241120\0000313866_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000313866_MDS.doc""] = ""0000313866_BM_6601622_ClearLLab10C_MALIGNANCY"","
510247,6704443,0000510247_BM_6704443_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,67,2024.12.04,2024.12.05,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,0.8%,Blasts,9.9×103/μL（dilution:N/Ax）,"115,116 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000510247_MDS.json,2024-12-06T12:36:44.4235948+08:00,71680,2024-12-06T16:16:32.1930383+08:00,0000510247_6704443_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241211\00005120247_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000510247_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a small number of normal myeloblasts population (0.8%) that is positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR. (2) The diagnostic flow score: 0 point. (3) Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise approximately 0.8% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241211\00005120247_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000510247_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241211\00005120247_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000510247_MDS.doc""] = ""0000510247_BM_6704443_ClearLLab10C_NO-MALIGNANCY"","
5109442,6289482,0005109442_BM_6289482_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.07,,男,68,2024.09.12,2024.09.13,XXX,Bone marrow,Refractory anemia,Acceptable,CD34/SSC,7.0%,Blasts,2.0×103/μL（dilution:N/Ax）,"46,220 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0005109442_MDS.json,2024-09-16T07:55:28.4966471+08:00,70144,2024-09-16T08:58:29.980202+08:00,0005109442_6289482_Bone marrow_Refractory anemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240919\0005109442_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0005109442_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 7% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, and HLA-DR. These cells also show aberrant expression of CD7 and CD56. The MDS diagnostic flow score: 2 points. Granulocytes showed abnormal pattern for CD13/CD16 and CD13/CD11b.",Myeloid blasts comprise approximately 7.0% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).,BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240919\0005109442_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0005109442_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240919\0005109442_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0005109442_MDS.doc""] = ""0005109442_BM_6289482_ClearLLab10C_MALIGNANCY"","
661886,6260003,0000661886_BM_6260003_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.031,,男,68,2024.09.04,2024.09.05,XXX,Bone marrow,Refractory anemia,Acceptable,CD34/SSC,3.1%,Blasts,4.3×103/μL（dilution:N/Ax）,"88,400 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000661886_MDS.json,2024-09-05T16:32:03.7417203+08:00,72192,2024-09-05T16:37:29.4641705+08:00,0000661886_6260003_Bone marrow_Refractory anemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240911\0000661886_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000661886_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 3.1% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, and HLA-DR. These cells also show aberrant expression of CD5 and CD7. The MDS diagnostic flow score: 3 points. Granulocytes showed abnormal pattern for CD13/CD16, and decreased SSC. Monocytes showed aberrant expression of CD56.",Myeloid blasts comprise approximately 3.1% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).,BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240911\0000661886_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000661886_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240911\0000661886_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000661886_MDS.doc""] = ""0000661886_BM_6260003_ClearLLab10C_MALIGNANCY"","
746351,5121766,0746351_BM_5121766_ClearLLab10C_MALIGNANCY,BM,Malignancy ,,0.076,,女,69,2023-10-04,2023-10-06,XXX,Bone marrow,AML suspected,Suboptimal (reason: clot  ),CD45/SSC,7.6%,Blasts,3.6×103/μL（dilution:N/A x）,"75,854 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0746351).json,2024-05-22T07:54:09.5722455+08:00,68096,2023-10-06T11:08:39.445+08:00,0746351_5121766_Bone marrow_AML suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231006\0746351_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0746351).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals an abnormal population, accounting for approximately 7.6% of total nucleated cells. These cells demonstrate positivity for CD34, CD33, CD38, CD117, CD123, and HLA-DR, but they are negative for MPO and CD13.",Abnormal myeloblasts comprise approximately 7.6% of all nucleated cells in the bone marrow.,BM,4|5,4,malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231006\0746351_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0746351).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231006\0746351_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0746351).doc""] = ""0746351_BM_5121766_ClearLLab10C_MALIGNANCY"","
1904968,5514147,1904968_BM_5514147_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Chronic Leukemia,0.05,,女,69,2024-03-01,2024-03-01,XXX,Bone marrow,AML suspected,Acceptable,CD34/SSC,5.5%,Blasts,19.7×103/μL（dilution: 5 x）,"99,706 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-CMML(1904968).json,2024-05-22T08:04:37.6532699+08:00,71680,2024-03-01T16:36:44.458+08:00,1904968_5514147_Bone marrow_AML suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240301\1904968_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-CMML(1904968).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 5% of total nucleated cells. These cells are positive for CD7(partial), CD13, CD33, CD38, CD64(partial), CD117, CD123, CD200, and HLA-DR. Granulocytes show abnormal pattern of CD13/CD16, and decreased SSC. In addition, there is a predominant monocytic population comprising approximately 51% of the cells analyzed, which shows aberrant expression of CD2 and CD56.",Immunophenotyping are compatible with chronic myelomonocytic leukemia (CMML). Please correlate with biopsy for .,BM,4|4,-1,CMML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240301\1904968_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-CMML(1904968).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240301\1904968_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-CMML(1904968).doc""] = ""1904968_BM_5514147_ClearLLab10C_MALIGNANCY"","
1745489,5484239,1745489_BM_5484239_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.04,,女,69,2024-02-19,2024-02-19,XXX,Bone marrow,B cell lymphoma,Acceptable,CD45/SSC,4.0%,Blasts,2.3×103/μL（dilution:N/A x）,"28,802 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1745489).json,2024-05-22T08:03:55.9618064+08:00,71680,2024-02-19T17:19:41.941+08:00,1745489_5484239_Bone marrow_B cell lymphoma_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240220\1745489_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1745489).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 17.4% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers. Furthermore, a small B cell population (about 0.7% of the cells analyzed) that is positive for CD19, CD20, CD200, and no signs of surface light-chain restriction. In addition, there is an abnormal myeloblast population comprising approximately 4.0% of the cells analyzed. These cells are positive for CD7(partial), CD13, CD33(bright), CD38, CD117, CD123 and HLA-DR, but lack of CD34. The MDS diagnostic flow score: 3 points. Granulocytes showed abnormal pattern for CD13/CD11b, CD13/CD16, and decreased SSC. Monocytes showed abnormal HLA-DR/CD11b pattern.","There is no evidence of lymphoma involvement; however, myeloid blasts comprise approximately 4.0% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).",BM,4|4,-1,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240220\1745489_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1745489).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240220\1745489_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1745489).doc""] = ""1745489_BM_5484239_ClearLLab10C_MALIGNANCY"","
661886,7209958,0000661886_BM_7209958_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.025,,男,69,2025.03.19,2025.03.21,XXX,Bone marrow,Refractory anemia,Acceptable,CD34/SSC,2.5%,Blasts,0.9×103/μL （dilution:N/Ax）,"21,174 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000661886_7209958_MDS.json,2025-03-21T11:08:34.3923463+08:00,73728,2025-03-21T11:37:57.3804097+08:00,0000661886_7209958_Bone marrow_Refractory anemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250319\0000661886_7209958_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000661886_7209958_MDS.doc,"Previous FCM results (2024.9.4): Myeloid blasts comprise approximately 3.1% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS). Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 2.5% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, and HLA-DR. These cells also show aberrant expression of CD5 and CD7. The MDS diagnostic flow score: 4 points. Granulocytes showed abnormal pattern for CD13/CD16, and decreased SSC.",Myeloid blasts comprise approximately 2.5% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).,BM,4|4,0,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250319\0000661886_7209958_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000661886_7209958_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250319\0000661886_7209958_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000661886_7209958_MDS.doc""] = ""0000661886_BM_7209958_ClearLLab10C_MALIGNANCY"","
78246,5367758,0078246_BM_5367758_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,69,2024-01-03,2024-01-03,XXX,Bone marrow,Pancytopenia,Acceptable,CD34/SSC,<0.1%,Blasts,0.4×103/μL（dilution:N/Ax）,"45,222 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MPN(0078246).json,2024-05-22T08:01:18.1162656+08:00,68096,2024-01-03T10:43:52.4629035+08:00,0078246_5367758_Bone marrow_Pancytopenia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240103\0078246_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MPN(0078246).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample. Additionally, the analysis showed a T cell population, accounting for about 43% of the cells analyzed, with no aberrant loss or aberrant expression. There was also a B cell population comprise approximately 4% of the cells analyzed, which showed negative for CD5, CD10, and no surface light-chain restriction.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and other immunophenotyping results are unremarkable.",BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240103\0078246_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MPN(0078246).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240103\0078246_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MPN(0078246).doc""] = ""0078246_BM_5367758_ClearLLab10C_NO-MALIGNANCY"","
661975,5246713,0661975_BM_5246713_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,69,2023-11-22,2023-11-23,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,<0.1%,Blasts,1.8×103/μL（dilution:N/Ax）,"86,496 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0661975).json,2024-05-22T07:57:36.1384736+08:00,68096,2023-11-23T15:32:45.6119364+08:00,0661975_5246713_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231123\0661975_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0661975).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable. (2) MDS diagnostic flow score: 0 point.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features. Please correlate with cytogenetic testing for .",BM,4|4,1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231123\0661975_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0661975).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231123\0661975_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0661975).doc""] = ""0661975_BM_5246713_ClearLLab10C_NO-MALIGNANCY"","
696232,6460988,0696232_BM_6460988_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.9,,男,70,2024.10.17,2024.10.17,XXX,Bone marrow,B-ALL suspected,Acceptable,CD45/SSC,90.0%,Blasts,15.4×103/μL（dilution: 5 x）,"125,577 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0696232_BALL.json,2024-10-17T14:16:56.2637929+08:00,72704,2024-10-17T15:14:49.1465959+08:00,0696232_6460988_Bone marrow_B-ALL suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0696232_BALL\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0696232_BALL.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals a predominant abnormal B cell population (about 90% of all the cells analyzed). These cells have small to medium nuclear size (based on forward-scatter signal) and show expression of CD34, CD10(bright), CD19, CD38(dim), CyCD79a, CD123, CD200, and HLA-DR. Additionally, they exhibit aberrant expression with a dim signal of CD45.",Immunophenotyping are compatible with precursor B-acute lymphoblastic leukemia (B-ALL).,BM,4|5,-1,B-ALL,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0696232_BALL\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0696232_BALL.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0696232_BALL\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0696232_BALL.doc""] = ""0696232_BM_6460988_ClearLLab10C_MALIGNANCY"","
394596,7209722,0000394596_BM_7209722_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.46,,女,70,2025.03.19,2025.03.21,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD45/SSC,46.0%,Blasts,5.9×103/μL（dilution:N/Ax）,"53,315 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000394596_7209722_AML(T).json,2025-03-21T11:08:23.8617278+08:00,77312,2025-03-21T11:21:07.4518967+08:00,0000394596_7209722_Bone marrow_AML (post-treatment follow-up)_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250319\0000394596_7209722_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000394596_7209722_AML(T).doc,"Previous FCM results (2024.10.23): Myeloid blasts comprise less than 0.1% of the total nucleated cells. Flow cytometric immunophenotyping of bone marrow aspirate reveals a predominant myeloblast population, comprising approximately 46% of the total nucleated cells. These cells are positive for MPO, CD34, CD13, CD33 (bright), CD38, CD64 (dim), CD117 (bright), and CD123 (bright). They are negative for CD7, CD10, CD19, CyCD3, CyCD79a, and HLA-DR. Granulocytes comprise approximately 5.3% of the nucleated bone marrow cells.",Immunophenotyping are compatible with acute myeloid leukemia (AML).,BM,4|5,0,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250319\0000394596_7209722_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000394596_7209722_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250319\0000394596_7209722_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000394596_7209722_AML(T).doc""] = ""0000394596_BM_7209722_ClearLLab10C_MALIGNANCY"","
1904968,6419084,0001904968_BM_6419084_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Chronic Leukemia,0.148,,女,70,2024.10.09,2024.10.14,XXX,Bone marrow,CMML,Acceptable,CD34/SSC,14.8%,Blasts,9.3×103/μL（dilution:N/Ax）,"85,598 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001904968_CMML.json,2024-10-14T09:04:31.6557809+08:00,72192,2024-10-14T11:05:04.2395065+08:00,0001904968_6419084_Bone marrow_CMML_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241016\0001904968_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001904968_CMML.doc,"Previous FCM results (2024.03.06): Immunophenotyping are compatible with chronic myelomonocytic leukemia (CMML). Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 14% of total nucleated cells. These cells are positive for CD4, CD11b(partial), CD13, CD33, CD34, CD38, CD64(partial), CD117, CD123, and HLA-DR. Granulocytes show abnormal pattern of CD13/CD16, and decreased SSC. In addition, there is a predominant monocytic population comprising approximately 40% of the cells analyzed, which shows a shift toward immature distribution of maturation stages.","Immunophenotyping are compatible with chronic myelomonocytic leukemia (CMML), and myeloblasts comprise approximately 14.8% of total nucleated cells.",BM,4|4,-1,CMML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241016\0001904968_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001904968_CMML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241016\0001904968_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001904968_CMML.doc""] = ""0001904968_BM_6419084_ClearLLab10C_MALIGNANCY"","
94804,5689040,0000094804_BM_5689040_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,70,2024-05-01,2024-05-01,XXX,Bone marrow,Anemia,Acceptable,CD34/SSC,0.4%,Blasts,17.6×103/μL（dilution:N/Ax）,"112,409 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0000094804).json,2024-05-22T08:07:27.2892801+08:00,69120,2024-05-01T16:41:50.645+08:00,0000094804_5689040_Bone marrow_Anemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240501\0000094804_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0000094804).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.3% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point. Granulocytes showed abnormal pattern for CD13/CD11b, CD13/CD16, and decreased SSC.","Myeloid blasts comprise approximately 0.4% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240501\0000094804_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0000094804).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240501\0000094804_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0000094804).doc""] = ""0000094804_BM_5689040_ClearLLab10C_NO-MALIGNANCY"","
394596,6490082,0000394596_BM_6490082_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,70,2024.10.24,2024.10.25,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,<0.1%,Blasts,4.3×103/μL（dilution:N/Ax）,"98,796 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000394596_AML(T).json,2024-10-25T10:15:16.3038382+08:00,67584,2024-10-25T10:31:30.883157+08:00,0000394596_6490082_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241031\0000394596_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000394596_AML(T).doc,"Previous FCM results (2024.05.22): Myeloid blasts comprise less than 0.1% of the total nucleated cells. Immunophenotyping of the bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable.",Myeloid blasts comprise less than 0.1% of the total nucleated cells.,BM,4|4,0,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241031\0000394596_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000394596_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241031\0000394596_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000394596_AML(T).doc""] = ""0000394596_BM_6490082_ClearLLab10C_NO-MALIGNANCY"","
394596,5766522,0000394596_BM_5766522_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,70,2024-05-21,2024-05-22,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,<0.1%,Blasts,4.7×103/μL（dilution:N/Ax）,"100,980 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_AML(T)(0000394596).json,2024-05-21T17:40:05.832876+08:00,65024,2024-05-22T07:42:23.697+08:00,0000394596_5766522_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240522\0000394596_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_AML(T)(0000394596).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable.",Myeloid blasts comprise less than 0.1% of the total nucleated cells.,BM,4|4,1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240522\0000394596_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_AML(T)(0000394596).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240522\0000394596_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_AML(T)(0000394596).doc""] = ""0000394596_BM_5766522_ClearLLab10C_NO-MALIGNANCY"","
696232,7311071,0696232_BM_7311071_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,71,2025.04.10,2025.04.10,XXX,Bone marrow,B-ALL (post-treatment follow up),Acceptable,CD19/SSC,5.3%,Other: B cells,7.6×103/μL（dilution:N/Ax）,"377,860 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0696232_7311071_BALL(T).json,2025-04-10T16:54:52.8336012+08:00,69632,2025-04-10T17:00:38.0664989+08:00,0696232_7311071_Bone marrow_B-ALL (post-treatment follow up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250416\0696232_7311071_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0696232_7311071_BALL(T).doc,"Previous FCM results (2024.10.17): Immunophenotyping are compatible with precursor B-acute lymphoblastic leukemia (B-ALL). Immunophenotyping of bone marrow aspirate by flow cytometry showed a normal lymphoblasts (hematogones) account for 5.2% of the total nucleated cells expressing CD45 (down-regulated), CD10, CD19, CD20, CD38, and CD200. Additionally, a small proportion of myeloblasts (0.7%) were detected in the bone marrow. Minimal residual disease (MRD) for B-ALL: <0.01%","Normal progenitor B cells account for 5.2% of the total nucleated cells, and minimal residual disease is less than 0.01%.",BM,4|4,-1,B-ALL MRD <0.01%,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250416\0696232_7311071_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0696232_7311071_BALL(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250416\0696232_7311071_BALL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0696232_7311071_BALL(T).doc""] = ""0696232_BM_7311071_ClearLLab10C_NO-MALIGNANCY"","
1520377,7415343,0001520377_BM_7415343_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,71,2025.04.29,2025.04.30,XXX,Bone marrow,"MDS, R/O leukemia",Acceptable,CD34/SSC,0.2%,Blasts,19.9×103/μL（dilution:N/Ax）,"154,281 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001520377_7415343_MDS.json,2025-04-30T16:45:20.5604432+08:00,69632,2025-04-30T16:50:06.2201105+08:00,"0001520377_7415343_Bone marrow_MDS, R/O leukemia_4|4.json",\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250430\0001520377_7415343_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001520377_7415343_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.2% of total nucleated cells, and these myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 0 point. Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise approximately 0.2% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,6,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250430\0001520377_7415343_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001520377_7415343_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250430\0001520377_7415343_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001520377_7415343_MDS.doc""] = ""0001520377_BM_7415343_ClearLLab10C_NO-MALIGNANCY"","
323775,7253502,0323775_BM_7253502_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.52,,男,72,2025.03.24,2025.03.31,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,52.6%,Blasts,5.9×103/μL（dilution:N/Ax）,"49,513 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0323775_7253502_AML.json,2025-03-31T10:01:37.893687+08:00,76800,2025-03-31T10:08:17.1000684+08:00,0323775_7253502_Bone marrow_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250331\0323775_7253502_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0323775_7253502_AML.doc,"Flow cytometric immunophenotyping of bone marrow aspirate reveals a predominant myeloblast population, comprising approximately 52% of the total nucleated cells. These cells are positive for MPO, CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR, but they are negative for CD7, CD10, CD19, CyCD3, and CyCD79a. Granulocytes comprise approximately 27% of the nucleated bone marrow cells.",Immunophenotyping are compatible with acute myeloid leukemia (AML).,BM,4|5,4,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250331\0323775_7253502_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0323775_7253502_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250331\0323775_7253502_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0323775_7253502_AML.doc""] = ""0323775_BM_7253502_ClearLLab10C_MALIGNANCY"","
5080718,5793006,5080718_BM_5793006_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.5,,男,72,2024.05.27,2024.05.27,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,49.4%,Blasts,5.2 ×103/μL（dilution:N/Ax）,"104,671 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_AML(5080718).json,2024-05-27T17:20:08.5585902+08:00,71168,2024-05-30T07:28:57.276+08:00,5080718_5793006_Bone marrow_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240528\5080718_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_AML(5080718).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry reveals a population of lymphoid cells (12.1%) with normal expression and no signs of surface light-chain restriction. Among the cells analyzed using CD38/CD138 gating, plasma cells account for approximately 0.2%, and they do not display any abnormal expression or evidence of cytoplasmic light-chain restriction. In addition, there is a predominant myeloblast population, comprising approximately 50% of the total nucleated cells. These cells are positive for CD34, MPO(bright), CD13, CD33, CD38, CD117, CD123 and HLA-DR. Additionally, they are negative for CD10, CyCD79a, and CyCD3. Myeloblasts show aberrant expression of CD7 and CD19.",Immunophenotyping are consistent with acute myeloid leukemia with maturation.,BM,4|5,-1,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240528\5080718_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_AML(5080718).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240528\5080718_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_AML(5080718).doc""] = ""5080718_BM_5793006_ClearLLab10C_MALIGNANCY"","
1660415,5332875,1660415_BM_5332875_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.13,,男,72,2023-12-20,2023-12-20,XXX,Bone marrow,MDS-suspected,Acceptable,CD34/SSC,13.0%,Blasts,16.2×103/μL（dilution: 3 x）,"114,754 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1660415).json,2024-05-22T07:59:32.6825646+08:00,71168,2023-12-20T17:01:10.834+08:00,1660415_5332875_Bone marrow_MDS-suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231220\1660415_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1660415).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 13% of total nucleated cells, as identified by the CD34-positive gating in the Blast region. These myeloblasts are positive for CD33, CD38, CD117, CD123, CD200, HLA-DR, and aberrant expression of CD7(partial). (2) MDS diagnostic flow score: 3 points. (3) Granulocytes showed abnormal pattern for CD13/CD16 and CD13/CD11b. (4) Monocytes are increased (26%)","Myeloid blasts comprise approximately 13.0% of total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS), please correlate with cytogenetic testing for .",BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231220\1660415_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1660415).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231220\1660415_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1660415).doc""] = ""1660415_BM_5332875_ClearLLab10C_MALIGNANCY"","
321805,5109962,0321805_BM_5109962_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.061,,男,72,2023-09-27,2023-09-28,XXX,Bone marrow,MDS suspected,Acceptable,CD45/SSC,6.1%,Blasts,13.5×103/μL（dilution:N/A x）,"199,895 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0321805).json,2024-05-22T07:52:35.0999586+08:00,68608,2023-10-04T08:02:55.221+08:00,0321805_5109962_Bone marrow_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202309\20230928\0321805_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0321805).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 6.1% of total nucleated cells. These myeloblasts are positive for CD13, CD33, CD38, CD117, CD123, CD200 and HLA-DR, but showed negativity for CD34. MDS diagnostic flow score: 3 points. Granulocytes showed abnormal pattern for CD13/CD16, CD13/CD11b and decreased SSC. Monocytes showed aberrant expression of CD56, and shift toward immature distribution of maturation stages.",Myeloid blasts comprise approximately 6.1% of total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS). Please correlate with cytogenetic testing for .,BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202309\20230928\0321805_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0321805).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202309\20230928\0321805_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0321805).doc""] = ""0321805_BM_5109962_ClearLLab10C_MALIGNANCY"","
5080718,6357312,5080718_BM_6357312_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.025,,男,72,2024.09.26,2024.09.27,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD45/SSC,2.5%,Blasts,6.7 ×103/μL（dilution:N/Ax）,"113,712 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5080718_AML(T).json,2024-09-26T13:28:58.6035618+08:00,68608,2024-09-27T09:55:34.3060294+08:00,5080718_6357312_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240930\5080718_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5080718_AML(T).doc,"Previous FCM results (2024.06.28): Presence of 0.1% polyclonal plasma cells and 0.1% myeloblasts in the bone marrow. Immunophenotyping of the bone marrow aspirate by flow cytometry reveals an abnormal population of myeloblasts, accounting for 2.5% of the total nucleated cells. These cells are positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR, and also display aberrant expression of CD7 and CD19.",A small proportion of residual myeloblasts (approximately 2.5%) were detected in the bone marrow.,BM,4|4,-1,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240930\5080718_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5080718_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240930\5080718_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5080718_AML(T).doc""] = ""5080718_BM_6357312_ClearLLab10C_MALIGNANCY"","
5080718,5935785,5080718_BM_5935785_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,72,2024.06.27,2024.06.28,XXX,Bone marrow,Multiple myeloma (post-treatment follow-up),Acceptable,CD45/SSC,0.1%,Blasts,7.4 ×103/μL（dilution:N/Ax）,"101,653 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5080718_MM(T).json,2024-06-28T11:36:19.3447089+08:00,68096,2024-06-28T11:51:16.747079+08:00,5080718_5935785_Bone marrow_Multiple myeloma (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202406\20240628\5080718_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5080718_MM(T).doc,"Previous FCM results (2024.05.27): immunophenotyping are consistent with acute myeloid leukemia with maturation. Immunophenotyping of the bone marrow aspirate by flow cytometry reveals a population of lymphoid cells (9%) with normal expression and no signs of surface light-chain restriction. Among the cells analyzed using CD38/CD138 gating, plasma cells account for approximately 0.1%, and they do not display any abnormal expression or evidence of cytoplasmic light-chain restriction. Myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.1% of total nucleated cells. These cells are positive for CD7(partial), CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR.",Presence of 0.1% polyclonal plasma cells and 0.1% myeloblasts in the bone marrow.,BM,4|4,-1,MM MRD-,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202406\20240628\5080718_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5080718_MM(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202406\20240628\5080718_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_5080718_MM(T).doc""] = ""5080718_BM_5935785_ClearLLab10C_NO-MALIGNANCY"","
5211369,7030082,5211369_BM_7030082_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,72,2025.02.11,2025.02.13,XXX,Bone marrow,"CML, R/O MDS or CMML",Acceptable,CD34/SSC,0.4%,Blasts,14.1×103/μL（dilution: N/A）,"133,866 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5211369_7030082_MPN.json,2025-02-11T15:29:13.9735376+08:00,69120,2025-02-13T11:52:09.6903908+08:00,"5211369_7030082_Bone marrow_CML, R/O MDS or CMML_4|4.json",\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\5211369_7030082_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5211369_7030082_MPN.doc,"Previous FCM results (2024.04.10): Myeloid blasts comprise approximately 0.3% of the total nucleated cells. Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a small number of myeloblasts population (0.4%) that is positive for CD34, CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The diagnostic flow score: 1 point. Granulocytes showed abnormal pattern for CD13/CD16.","Myeloid blasts comprise approximately 0.4% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,0,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\5211369_7030082_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5211369_7030082_MPN.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\5211369_7030082_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-5211369_7030082_MPN.doc""] = ""5211369_BM_7030082_ClearLLab10C_NO-MALIGNANCY"","
1032538,5204316,1032538_BM_5204316_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,72,2023-11-08,2023-11-09,XXX,Bone marrow,"Aplastic anemia, R/O MDS",Acceptable,CD34/SSC,0.1%,Blasts,2.8×103/μL（dilution:N/Ax）,"154,060 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1032538).json,2024-05-22T07:57:04.0673906+08:00,65536,2023-11-10T09:10:44.366+08:00,"1032538_5204316_Bone marrow_Aplastic anemia, R/O MDS_4|4.json",\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231110\1032538_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1032538).doc,"(1) Myeloblasts account for 0.1% of total nucleated cells. (2) Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a myeloblast population that is positive for CD34, CD13, CD33, CD38, CD117, CD123 and HLA-DR. (3) Diagnostic flow score: 1 point. (4) Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise approximately 0.1% of the total nucleated cells, and there are no myelodysplastic syndrome (MDS)-related features.",BM,4|4,2,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231110\1032538_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1032538).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231110\1032538_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1032538).doc""] = ""1032538_BM_5204316_ClearLLab10C_NO-MALIGNANCY"","
321805,6512447,0000321805_BM_6512447_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.752,,男,73,2024.10.28,2024.10.29,XXX,Bone marrow,AML suspected.,Acceptable,CD45/SSC,75.2%,Blasts,0.6×103/μL（dilution:N/Ax）,"14,408 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000321805_AML.json,2024-10-29T16:50:56.0077923+08:00,75264,2024-10-29T17:06:00.6768592+08:00,0000321805_6512447_Bone marrow_AML suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241031\0000321805_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000321805_AML.doc,"Previous FCM results (2024.07.10): Myeloid blasts comprise approximately 7.6% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS). Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant myeloblast population, comprising approximately 75.2% of the total nucleated cells. These cells are positive for CD7(dim), CD34(partial), MPO, CD13, CD33, CD38, CD117, CD123, and HLA-DR. Additionally, they are negative for CD10, CD19, CyCD3 and CyCD79a.",Immunophenotyping are compatible with acute myeloid leukemia without maturation.,BM,4|5,0,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241031\0000321805_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000321805_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241031\0000321805_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000321805_AML.doc""] = ""0000321805_BM_6512447_ClearLLab10C_MALIGNANCY"","
321805,5970908,0000321805_BM_5970908_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.076,,男,73,2024.07.03,2024.07.04,XXX,Bone marrow,MDS suspected,Acceptable,CD45/SSC,7.6%,Blasts,1.17×103/μL（dilution:N/Ax）,"101,032 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0000321805).json,2024-07-04T12:18:55.1169508+08:00,71680,2024-07-04T14:20:43.208781+08:00,0000321805_5970908_Bone marrow_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240710\0000321805_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0000321805).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 8% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD38, CD117, CD123, and HLA-DR. These cells lack CD34, showing aberrant expression. The MDS diagnostic flow score: 2 points. Granulocytes showed abnormal pattern for CD15/CD10 and CD13/CD16, and decreased SSC.",Myeloid blasts comprise approximately 7.6% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).,BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240710\0000321805_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0000321805).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240710\0000321805_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0000321805).doc""] = ""0000321805_BM_5970908_ClearLLab10C_MALIGNANCY"","
1660415,5771983,0001660415_BM_5771983_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.073,,男,73,2024-05-21,2024-05-22,XXX,Bone marrow,CMML,Acceptable,CD34/SSC,7.3%,Blasts,7.8×103/μL（dilution : N/Ax）,"93,132 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-CMML(0001660415).json,2024-05-22T08:39:11.8600942+08:00,72704,2024-05-22T16:12:18.335+08:00,0001660415_5771983_Bone marrow_CMML_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240522\0001660415_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-CMML(0001660415).doc,"Previous FCM results (2024.03.25): CMML, abnormal myeloblasts comprise approximately 0.9%. Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 7% of all cells analyzed. These myeloblasts are positive for CD34, CD13, CD33, CD38, CD64, CD117, CD123, CD200, and HLA-DR. These cells with aberrant expression of CD7. The MDS diagnostic flow score: 3 points.",Residual myeloblasts comprise approximately 7.3% of the total nucleated cells in bone marrow.,BM,4|4,0,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240522\0001660415_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-CMML(0001660415).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240522\0001660415_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-CMML(0001660415).doc""] = ""0001660415_BM_5771983_ClearLLab10C_MALIGNANCY"","
323775,7433104,0323775_BM_7433104_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.044,,男,73,2025.05.02,2025.05.05,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,4.4%,Blasts,4.2×103/μL（dilution:N/Ax）,"105,443 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0323775_7253502_AML(T).json,2025-05-05T11:31:18.2499272+08:00,71168,2025-05-07T08:53:56.0188817+08:00,0323775_7433104_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202505\20250507\0323775_7433104_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0323775_7253502_AML(T).doc,"Previous FCM results (2025.04.01): Immunophenotyping are compatible with acute myeloid leukemia (AML). Immunophenotyping of the bone marrow aspirate by flow cytometry identified myeloblasts gated by CD34/SSC in the blast region, comprising 4.4% of total nucleated cells. These cells are positive for CD13, CD33 (dim), CD38, CD117 (bright), CD123 (dim), and HLA-DR.",Myeloid blasts comprise approximately 4.4% of the total nucleated cells.,BM,4|4,-1,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202505\20250507\0323775_7433104_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0323775_7253502_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202505\20250507\0323775_7433104_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0323775_7253502_AML(T).doc""] = ""0323775_BM_7433104_ClearLLab10C_MALIGNANCY"","
1145962,6726502,0001145962_BM_6726502_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,73,2024.12.09,2024.12.10,XXX,Bone marrow,R/O MDS,Suboptimal (reason:   clot      ),CD34/SSC,0.2%,Blasts,6.3×103/μL（dilution:N/Ax）,"110,627 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001145962_MDS.json,2024-12-10T16:13:31.8132963+08:00,71168,2024-12-10T17:15:49.8631074+08:00,0001145962_6726502_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241211\0001145962_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001145962_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a small number of normal myeloblasts population (0.2%) that is positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR. The diagnostic flow score: 1 point. Decreased SSC of granulocytes. ※患者骨髓檢體含有凝塊(clot)，可能影響分析結果的準確度，報告判讀時請小心。","Myeloid blasts comprise approximately 0.2% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241211\0001145962_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001145962_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241211\0001145962_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001145962_MDS.doc""] = ""0001145962_BM_6726502_ClearLLab10C_NO-MALIGNANCY"","
1711104,5802408,1711104_BM_5802408_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,73,2024.05.29,2024.05.30,XXX,Bone marrow,Essential thrombocythemia,Acceptable,CD34/SSC,0.3%,Blasts,15.6×103/μL（dilution:N/Ax）,"100,021 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1711104).json,2024-05-30T12:22:15.884425+08:00,69120,2024-05-30T15:36:13.71746+08:00,1711104_5802408_Bone marrow_Essential thrombocythemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240530\1711104_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1711104).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.3% of total nucleated cells. These cells are positive for CD7(partial), CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point. Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise approximately 0.3% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,6,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240530\1711104_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1711104).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240530\1711104_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1711104).doc""] = ""1711104_BM_5802408_ClearLLab10C_NO-MALIGNANCY"","
854902,6633393,0854902_BM_6633393_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Chronic Leukemia,0.11,,女,74,2024.11.21,2024.11.22,XXX,Bone marrow,CMML,Acceptable,CD34/SSC,11.6%,Blasts,2.1×103/μL（dilution : N/A x）,"87,344 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0854902_CMML.json,2024-11-22T11:59:01.3075923+08:00,72704,2024-11-22T16:42:07.7484527+08:00,0854902_6633393_Bone marrow_CMML_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0854902_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0854902_CMML.doc,"Previous FCM results (2023.04.12): CMML(外送至彰基代檢). Immunophenotyping of the bone marrow aspirate by flow cytometry revealed an abnormal population comprising approximately 11% of all cells analyzed. These myeloblasts are positive for CD34, CD4, CD13, CD33, CD38, CD64(dim), CD117(partial), CD123, and HLA-DR. Additionally, these cells exhibit aberrant expression of CD5 and CD7. Immature monocytes comprise approximately 13.2% of total nucleated cells. these cells are positive for CD11b, CD14, CD15 (dim), CD33 (bright), CD38, CD64 (bright), CD123, and HLA-DR. The MDS diagnostic flow score: 4 points.","Immunophenotyping, together with morphological findings, are compatible with chronic myelomonocytic leukemia.",BM,4|4,-1,CMML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0854902_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0854902_CMML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0854902_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0854902_CMML.doc""] = ""0854902_BM_6633393_ClearLLab10C_MALIGNANCY"","
1448287,6622604,0001448287_BM_6622604_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,74,2024.11.19,2024.11.21,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,0.2%,Blasts,6.5×103/μL（dilution:N/Ax）,"113,505 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001448287_MDS.json,2024-11-20T17:30:26.4294233+08:00,70144,2024-11-21T09:11:13.0786483+08:00,0001448287_6622604_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0001448287_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001448287_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.2% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The lymphoid cells (11%) with normal expression and no signs of surface light-chain restriction. Among the cells analyzed using CD38/SSC gating, plasma cells account for approximately 0.1%, and they do not display any abnormal expression.",The presence of 0.2% myeloblasts and 0.1% plasma cells in the bone marrow requires correlation with the pathological report for further .,BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0001448287_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001448287_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0001448287_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001448287_MDS.doc""] = ""0001448287_BM_6622604_ClearLLab10C_NO-MALIGNANCY"","
556273,7343463,0000556273_BM_7343463_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,74,2025.04.16,2025.04.16,XXX,Bone marrow,Polycythemia vera,Acceptable,CD34/SSC,0.1%,Blasts,13.5×103/μL（dilution: N/A）,"120,925 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000556273_7343463_MPN.json,2025-04-16T15:02:37.5765008+08:00,68608,2025-04-16T16:44:25.3710582+08:00,0000556273_7343463_Bone marrow_Polycythemia vera_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250423\0000556273_7343463_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000556273_7343463_MPN.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a small number of myeloblasts population (0.1%) that is positive for CD34, CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The diagnostic flow score: 1 point. Decreased SSC of granulocytes, and monocytes display aberrant expression of CD56.","Myeloid blasts comprise approximately 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250423\0000556273_7343463_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000556273_7343463_MPN.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202504\20250423\0000556273_7343463_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000556273_7343463_MPN.doc""] = ""0000556273_BM_7343463_ClearLLab10C_NO-MALIGNANCY"","
975911,7165982,0000975911_BM_7165982_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,74,2025.03.10,2025.03.10,XXX,Bone marrow,APL (post-treatment follow-up),Acceptable,CD45/SSC,<0.1%,Leukemic cells,3.4×103/μL（dilution:N/Ax）,"105,358 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000975911_7023422_APL.json,2025-03-10T11:46:07.442702+08:00,72192,2025-03-10T16:10:13.0719368+08:00,0000975911_7165982_Bone marrow_APL (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250312\0000975911_7165982_APL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000975911_7023422_APL.doc,"Previous FCM results (2025.02.10): Immunophenotyping are consistent with acute promyelocytic leukemia (APL). Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 16% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 4% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Leukemic cells accounted for less than 0.1% of the total nucleated cells in the granulocyte region gated by CD45/SSC. However, due to the very low number of leukemic cells in the sample, fluorescence intensity could not be evaluated, and other immunophenotyping results were unremarkable.",No abnormal immunophenotypes associated with APL are found with flow cytometry.,BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250312\0000975911_7165982_APL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000975911_7023422_APL.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250312\0000975911_7165982_APL(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000975911_7023422_APL.doc""] = ""0000975911_BM_7165982_ClearLLab10C_NO-MALIGNANCY"","
232958,6906163,0000232958_BM_6906163_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.86,,男,75,2025.01.14,2025.01.16,XXX,Bone marrow,R/O AML,Acceptable,CD45/SSC,86.8%,Blasts,16.2×103/μL（dilution:N/Ax）,"90,223 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000232958_6906163_AML.json,2025-01-16T11:47:34.4849172+08:00,74752,2025-01-16T12:31:29.4337121+08:00,0000232958_6906163_Bone marrow_R/O AML_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0000232958_6906163_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000232958_6906163_AML.doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry reveals a predominant myeloblast population, accounting for approximately 86% of the total nucleated cells. These cells are positive for MPO, CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR, but negative for CD7, CD10, CD19, CyCD3, and CyCD79a. Granulocytes comprise approximately 7% of the nucleated bone marrow cells.",Immunophenotyping are compatible with acute myeloid leukemia (AML) without maturation.,BM,4|5,4,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0000232958_6906163_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000232958_6906163_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0000232958_6906163_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000232958_6906163_AML.doc""] = ""0000232958_BM_6906163_ClearLLab10C_MALIGNANCY"","
851270,5526348,0851270_BM_5526348_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.072,,女,75,2024-03-06,2024-03-07,XXX,Bone marrow,AML suspected,Acceptable,CD34/SSC,7.2%,Blasts,14.1×103/μL（dilution:N/Ax）,"98,490 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0851270).json,2024-05-22T08:04:56.0739165+08:00,70656,2024-03-07T10:18:59.37+08:00,0851270_5526348_Bone marrow_AML suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240307\0851270_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0851270).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 7% of all cells analyzed. These myeloblasts are positive for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR. These cells with aberrant expression of CD7. The MDS diagnostic flow score: 4 points. Granulocytes showed abnormal pattern for CD13/CD11b, CD13/CD16, and decreased SSC.",Myeloid blasts comprise approximately 7.2% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).,BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240307\0851270_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0851270).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240307\0851270_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0851270).doc""] = ""0851270_BM_5526348_ClearLLab10C_MALIGNANCY"","
1458961,6464182,0001458961_BM_6464182_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.064,,女,75,2024.10.17,2024.10.18,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,6.4%,Blasts,6.1×103/μL（dilution:N/Ax）,"113,748 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001458961_MDS.json,2024-10-18T16:57:34.7732721+08:00,71168,2024-10-18T17:25:07.7439438+08:00,0001458961_6464182_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0001458961_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001458961_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 6% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD64(partial), CD117, CD123, CD200, and HLA-DR. These cells also show aberrant expression of CD2. The MDS diagnostic flow score: 3 points. Granulocytes showed abnormal pattern for CD13/CD16 and CD13/CD11b, and decreased SSC. Monocytes showed aberrant expression of CD56.",Myeloid blasts comprise approximately 6.4% of the total nucleated cells. Immunophenotyping is compatible with myelodysplastic syndromes (MDS).,BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0001458961_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001458961_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0001458961_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001458961_MDS.doc""] = ""0001458961_BM_6464182_ClearLLab10C_MALIGNANCY"","
9012784,5450972,9012784_BM_5450972_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.106,,女,76,2024-02-05,2024-02-05,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD45/SSC,10.6%,Blasts,1.2 ×103/μL（dilution:N/Ax）,"67,109 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(9012784).json,2024-05-22T08:03:19.3305206+08:00,73216,2024-02-05T17:05:47.387+08:00,9012784_5450972_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240205\9012784_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(9012784).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals an abnormal population, accounting for approximately 10% of total nucleated cells. These cells demonstrate positivity for CD34, CD13, CD33(partial), CD38, CD117(bright), CD123, and HLA-DR(bright). Additionally, they displayed multiple aberrant expression of CD2, CD5, CD19 and CD56. Monocytes are increased in the bone marrow.",Myeloid blasts with multiple aberrancies comprise approximately 10.6% of all nucleated cells.,BM,4|4,-1,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240205\9012784_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(9012784).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202402\20240205\9012784_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(9012784).doc""] = ""9012784_BM_5450972_ClearLLab10C_MALIGNANCY"","
796505,5313950,0796505_BM_5313950_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,76,2023-12-14,2023-12-15,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,<0.1%,Blasts,2.3×103/μL（dilution:N/Ax）,"100,972 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MDS(0796505).json,2024-05-22T07:58:54.0512086+08:00,68096,2023-12-19T16:15:35.1161554+08:00,0796505_5313950_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231215\0796505_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MDS(0796505).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable. (2) MDS diagnostic flow score: 1 point.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231215\0796505_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MDS(0796505).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231215\0796505_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_MDS(0796505).doc""] = ""0796505_BM_5313950_ClearLLab10C_NO-MALIGNANCY"","
126431,6628902,0000126431_BM_6628902_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,76,2024.11.20,2024.11.21,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,0.5%,Blasts,5.9×103/μL（dilution:N/Ax）,"116,521 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000126431_MDS.json,2024-11-21T09:25:58.5464094+08:00,69632,2024-11-21T11:35:52.3574976+08:00,0000126431_6628902_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0000126431_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000126431_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.5% of total nucleated cells. These cells are positive for CD7(partial), CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 0 point.","Myeloid blasts comprise approximately 0.5% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,7,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0000126431_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000126431_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241126\0000126431_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000126431_MDS.doc""] = ""0000126431_BM_6628902_ClearLLab10C_NO-MALIGNANCY"","
844198,6456722,0000844198_BM_6456722_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.016,,男,77,2024.10.16,2024.10.17,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD45/SSC,1.6%,Blasts,0.8 ×103/μL（dilution:N/Ax）,"37,798 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000844198_AML(T).json,2024-10-17T14:12:14.5742141+08:00,69632,2024-10-17T16:43:42.7476727+08:00,0000844198_6456722_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0000844198_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000844198_AML(T).doc,"Previous FCM results (2024.05.01): Myeloid blasts comprise approximately 0.2% of the total nucleated cells. Immunophenotyping of the bone marrow aspirate by flow cytometry reveals an atypical population of myeloblasts, accounting for 1.6% of the total nucleated cells. These cells are positive with homogeneous intensity pattern for CD34, CD13, CD33, CD38, CD117, CD123, and HLA-DR.",A small number of myeloblasts is found in bone marrow (about 1.6% of the total nucleated cells). Clinical correlation is suggested.,BM,4|4,0,AML MRD+,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0000844198_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000844198_AML(T).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202410\20241023\0000844198_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000844198_AML(T).doc""] = ""0000844198_BM_6456722_ClearLLab10C_MALIGNANCY"","
1206476,6033826,1206476_BM_6033826_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Chronic Leukemia,0.015,,男,77,2024.07.15,2024.07.16,XXX,Bone marrow,CML,Acceptable,CD34/SSC,1.5%,Blasts,18.1×103/μL（dilution:10 x）,"100,688 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1206476_CML.json,2024-07-16T08:56:16.1671902+08:00,71680,2024-07-16T09:04:24.174838+08:00,1206476_6033826_Bone marrow_CML_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240717\1206476_CML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1206476_CML.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 1.5% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. These cells show aberrant expression of CD5.",Myeloid blasts comprise approximately 1.5% of the total nucleated cells.,BM,4|4,3,CML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240717\1206476_CML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1206476_CML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240717\1206476_CML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-1206476_CML.doc""] = ""1206476_BM_6033826_ClearLLab10C_MALIGNANCY"","
844198,5200902,0844198_PB_5200902_ClearLLab10C_NO-MALIGNANCY,PB,No Malignancy,No Malignancy,,,男,77,2023-11-06,2023-11-08,XXX,Other:周邊血,"AML, follow-up.",Acceptable,CD34/SSC,<0.1%,Blasts,3.3×103/μL（dilution:N/A x）,"90,542 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0844198).json,2024-05-22T07:56:47.7969073+08:00,67584,2023-11-15T11:39:44.182+08:00,"0844198_5200902_Other:周邊血_AML, follow-up_4|4.json",\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231108\0844198_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0844198).doc,"Immunophenotyping of peripheral blood leukocytes by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable.",No abnormal immunophenotypes are found with flow cytometry.,PB,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231108\0844198_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0844198).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231108\0844198_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0844198).doc""] = ""0844198_PB_5200902_ClearLLab10C_NO-MALIGNANCY"","
1318485,5207962,1318485_BM_5207962_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,77,2023-11-09,2023-11-10,XXX,Bone marrow,MDS suspected,Acceptable,CD34/SSC,0.4%,Blasts,3.0×103/μL（dilution:N/Ax）,"111,146 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1318485).json,2024-05-22T07:57:11.417609+08:00,66048,2023-11-10T16:39:11.772+08:00,1318485_5207962_Bone marrow_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231110\1318485_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1318485).doc,"(1) Myeloblasts account for 0.4% of total nucleated cells. (2) Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a myeloblast population that is positive for CD34, CD13, CD33, CD38, CD117, CD123 and HLA-DR. (3) Diagnostic flow score: 1 point. (4) Slight decrease in side scatter (SSC) of granulocytes.","Myeloid blasts comprise approximately 0.4% of the total nucleated cells, and there are no myelodysplastic syndrome (MDS)-related features.",BM,4|4,2,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231110\1318485_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1318485).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231110\1318485_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1318485).doc""] = ""1318485_BM_5207962_ClearLLab10C_NO-MALIGNANCY"","
697963,6952164,0697963_BM_6952164_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,77,2025.01.23,2025.01.23,XXX,Bone marrow,Essential thrombocythemia,Acceptable,CD34/SSC,0.4%,Blasts,6.7×103/μL（dilution:N/Ax）,"192,102 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0697963_6952164_MPN.json,2025-01-23T16:07:27.5776142+08:00,69120,2025-01-23T16:18:10.1171655+08:00,0697963_6952164_Bone marrow_Essential thrombocythemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250131\0697963_6952164_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0697963_6952164_MPN.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.4% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 0 point.","Myeloid blasts comprise approximately 0.4% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,7,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250131\0697963_6952164_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0697963_6952164_MPN.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250131\0697963_6952164_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0697963_6952164_MPN.doc""] = ""0697963_BM_6952164_ClearLLab10C_NO-MALIGNANCY"","
167157,7229246,0167157_BM_7229246_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.86,,男,78,2025.03.24,2025.03.25,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,86.5%,Blasts,6.6×103/μL（dilution:N/Ax）,"99,571 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0167157_7229246_AML.json,2025-03-25T08:33:12.8218558+08:00,75776,2025-03-25T08:43:12.6741342+08:00,0167157_7229246_Bone marrow_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250326\0167157_7229246_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0167157_7229246_AML.doc,"Flow cytometric immunophenotyping of bone marrow aspirate reveals a predominant myeloblast population, comprising approximately 86% of the total nucleated cells. These cells are positive for CD34 (bright), CD13, CD33, CD117, CD123 (bright), and HLA-DR, but they are negative for MPO, CD10, CD19, CD38, CyCD3, and CyCD79a. The myeloblast population exhibits aberrant expression of CD7 and CD56. Granulocytes comprise approximately 6% of the nucleated bone marrow cells.",Immunophenotyping are compatible with acute myeloid leukemia (AML).,BM,4|5,4,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250326\0167157_7229246_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0167157_7229246_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250326\0167157_7229246_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0167157_7229246_AML.doc""] = ""0167157_BM_7229246_ClearLLab10C_MALIGNANCY"","
69648,6578368,0000069648_BM_6578368_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.35,,男,78,2024.11.11,2024.11.13,XXX,Bone marrow,R/O leukemia,Acceptable,CD45/SSC,35.0%,Blasts,12.1×103/μL（dilution:N/Ax）,"131,023 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000069648_AML.json,2024-11-12T16:42:12.1099661+08:00,74752,2024-11-12T17:14:40.7684432+08:00,0000069648_6578368_Bone marrow_R/O leukemia_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241113\0000069648_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000069648_AML.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant myeloblast population, comprising approximately 35% of the total nucleated cells. These cells are positive for CD34, MPO (dim), CD13, CD33, CD38, CD117, CD123, and HLA-DR. Additionally, they are negative for CD10, CD19, CyCD3 and CyCD79a. These cells exhibit aberrant expression of CD7 and CD15.",Immunophenotyping are compatible with acute myeloid leukemia with maturation.,BM,4|5,4,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241113\0000069648_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000069648_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241113\0000069648_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000069648_AML.doc""] = ""0000069648_BM_6578368_ClearLLab10C_MALIGNANCY"","
2084379,5272318,2084379_BM_5272318_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.03,,男,79,2023-12-01,2023-12-04,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD45/SSC,3.0%,Blasts,0.6×103/μL（dilution:N/Ax）,"25,240 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(2084379).json,2024-05-22T07:58:25.4502046+08:00,70144,2023-12-04T08:09:18.909+08:00,2084379_5272318_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231204\2084379_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(2084379).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 3.0% of the cells analyzed. These cells showed positivity for CD13, CD33, CD34(bright), CD38(bright), CD117(bright), CD123(bright), and HLA-DR(bright). Additionally, they displayed aberrant expression of CD7(bright) and CD19(dim).",A small proportion of residual myeloblasts (approximately 3.0%) were detected in the bone marrow.,BM,4|4,-1,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231204\2084379_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(2084379).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202312\20231204\2084379_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(2084379).doc""] = ""2084379_BM_5272318_ClearLLab10C_MALIGNANCY"","
1669789,5410943,1669789_BM_5410943_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,79,2024-01-22,2024-01-23,XXX,Bone marrow,MDS/MPN suspected,Acceptable,CD34/SSC,<0.1%,Blasts,3.7×103/μL（dilution:N/Ax）,"150,805 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1669789).json,2024-05-22T08:02:59.9498402+08:00,66048,2024-01-23T08:19:09.609+08:00,1669789_5410943_Bone marrow_MDS/MPN suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240122\1669789_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1669789).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable. MDS diagnostic flow score: 1 point. Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240122\1669789_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1669789).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240122\1669789_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1669789).doc""] = ""1669789_BM_5410943_ClearLLab10C_NO-MALIGNANCY"","
144379,5807729,0144379_BM_5807729_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,79,2024.05.30,2024.05.31,XXX,Bone marrow,Essential thrombocythemia,Acceptable,CD34/SSC,0.1%,Blasts,4.8×103/μL（dilution:N/Ax）,"57, 771events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(01443794).json,2024-05-31T16:07:23.3043757+08:00,69120,2024-05-31T16:12:00.6128205+08:00,0144379_5807729_Bone marrow_Essential thrombocythemia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240531\0144379_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(01443794).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.1% of total nucleated cells. These cells are positive for CD13, CD33(partial), CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point. Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise approximately 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,6,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240531\0144379_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(01443794).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240531\0144379_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(01443794).doc""] = ""0144379_BM_5807729_ClearLLab10C_NO-MALIGNANCY"","
2203433,5749170,0002203433_BM_5749170_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,79,2024-05-15,2024-05-16,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,0.5%,Blasts,8.4×103/μL（dilution:N/Ax）,"106,344 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0002203433).json,2024-05-22T08:08:21.7012224+08:00,69120,2024-05-16T12:02:08.857+08:00,0002203433_5749170_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240516\0002203433_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0002203433).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.5% of total nucleated cells. These cells are positive for CD7(dim), CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 0 point. Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise approximately 0.5% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,6,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240516\0002203433_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0002203433).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240516\0002203433_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0002203433).doc""] = ""0002203433_BM_5749170_ClearLLab10C_NO-MALIGNANCY"","
646571,5578008,0646571_PB_5578008_ClearLLab10C_MALIGNANCY,PB,Malignancy ,Acute Leukemia,0.25,,男,81,2024-03-28,2024-03-29,XXX,Other:周邊血,AML suspected,Acceptable,CD45/SSC,25.0%,Blasts,4.6×103/μL（dilution: N/A x）,"98,998 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0646571).json,2024-05-22T08:05:43.4955811+08:00,71168,2024-03-29T11:32:04.1005181+08:00,0646571_5578008_Other:周邊血_AML suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240328\0646571_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0646571).doc,"Immunophenotyping of peripheral blood leukocytes by flow cytometry reveals the presence of a predominant myeloblast population, comprising approximately 25% of the total nucleated cells. These cells are positive for CD34, MPO, CD13, CD14(dim), CD33, CD38, CD117, CD123, CD200, and HLA-DR. Additionally, they are negative for CD7, CyCD79a and CyCD3. Myeloblasts show aberrant expression of CD19(partial) and CD56.","Immunophenotyping, together with the presence of blasts with Auer’s rods in the peripheral blood, are consistent with acute myeloid leukemia (AML).",PB,4|5,-1,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240328\0646571_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0646571).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240328\0646571_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0646571).doc""] = ""0646571_PB_5578008_ClearLLab10C_MALIGNANCY"","
1777,5138701,0001777_PB_5138701_ClearLLab10C_NO-MALIGNANCY,PB,No Malignancy,No Malignancy,,,男,81,2023-10-12,2023-10-13,XXX,Other:周邊血,MPN suspected,Acceptable,CD34/SSC,<0.1%,Blasts,15.0×103/μL（dilution: 3x）,"101,402events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(0001777).json,2024-05-22T07:54:22.4425897+08:00,67584,2023-10-13T16:56:55.58+08:00,0001777_5138701_Other:周邊血_MPN suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231013\0001777_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(0001777).doc,"(1) Immunophenotyping of peripheral blood leukocytes by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable. (2) MDS diagnostic flow score: 1 point. (3) Neutrophils are increased (>90%).","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and there are no myelodysplastic syndrome (MDS)-related features. Please correlate with cytogenetic testing for .",PB,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231013\0001777_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(0001777).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231013\0001777_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(0001777).doc""] = ""0001777_PB_5138701_ClearLLab10C_NO-MALIGNANCY"","
1777,5265764,0001777_BM_5265764_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,81,2023-11-29,2023-11-30,XXX,Bone marrow,Polycythemia vera,Acceptable,CD34/SSC,<0.1%,Blasts,5.3×103/μL（dilution:N/Ax）,"126,356 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0001777).json,2024-05-22T07:57:42.0386808+08:00,67072,2023-11-30T15:01:30.428+08:00,0001777_5265764_Bone marrow_Polycythemia vera_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231130\0001777_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0001777).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable. MDS diagnostic flow score: 1 point. Neutrophils are increased (>90%).","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231130\0001777_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0001777).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231130\0001777_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0001777).doc""] = ""0001777_BM_5265764_ClearLLab10C_NO-MALIGNANCY"","
97279,7066543,0000097279_BM_7066543_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.84,,男,82,2025.02.18,2025.02.19,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,84.2%,Blasts,18.9×103/μL（dilution:4x）,"99,220 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000097279_7066543_AML.json,2025-02-18T15:55:49.1326143+08:00,73728,2025-02-19T09:13:16.8370697+08:00,0000097279_7066543_Bone marrow_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\0000097279_7066543_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000097279_7066543_AML.doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry reveals a predominant myeloblast population, accounting for approximately 84% of the total nucleated cells. These cells are positive for MPO, CD13, CD33, CD38, CD117, CD123, and HLA-DR, but negative for CD34, CD7, CD10, CD19, CyCD3, and CyCD79a. ※患者骨髓檢體操作時間已超出採檢後24小時，可能影響分析準確度，報告判讀時請小心。",Immunophenotyping are compatible with acute myeloid leukemia (AML).,BM,4|5,-1,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\0000097279_7066543_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000097279_7066543_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250219\0000097279_7066543_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000097279_7066543_AML.doc""] = ""0000097279_BM_7066543_ClearLLab10C_MALIGNANCY"","
2105729,6917522,0002105729_BM_6917522_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.32,,女,82,2025.01.16,2025.01.17,XXX,Bone marrow,R/O MDS or AML,Acceptable,CD45/SSC,32.6%,Blasts,4.1×103/μL（dilution:N/Ax）,"91,003 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002105729_6917522_AML.json,2025-01-17T13:33:34.0069042+08:00,75776,2025-01-20T14:52:26.8656541+08:00,0002105729_6917522_Bone marrow_R/O MDS or AML_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0002105729_6917522_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002105729_6917522_AML.doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry reveals a predominant myeloblast population, accounting for approximately 32% of the total nucleated cells. These cells are positive for CD34, CD13 (dim), CD33, CD38, CD117, CD123, and HLA-DR, but negative for CD7, CD10, CD19, CyCD3, and CyCD79a. MPO: 5.8% Granulocytes comprise approximately 21% of the nucleated bone marrow cells.",Immunophenotyping are compatible with acute myeloid leukemia (AML) with maturation.,BM,4|5,4,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0002105729_6917522_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002105729_6917522_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202501\20250122\0002105729_6917522_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0002105729_6917522_AML.doc""] = ""0002105729_BM_6917522_ClearLLab10C_MALIGNANCY"","
1451526,5232301,1451526_PB_5232301_ClearLLab10C_NO-MALIGNANCY,PB,No Malignancy,No Malignancy,,,女,82,2023-11-17,2023-11-17,XXX,Other: 周邊血,MDS suspected,Acceptable,CD34/SSC,<0.1%,Blasts,5.4×103/μL（dilution:N/Ax）,"179,456 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1451526).json,2024-05-22T07:57:26.5581373+08:00,67584,2023-11-21T17:01:23.127+08:00,1451526_5232301_Other: 周邊血_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231117\1451526_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1451526).doc,"Immunophenotyping of peripheral blood leukocytes by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region. However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable. (2) MDS diagnostic flow score: invalid.",No myelodysplastic syndrome (MDS)-related features are found with immunophenotyping by flow cytometry.,PB,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231117\1451526_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1451526).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202311\20231117\1451526_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(1451526).doc""] = ""1451526_PB_5232301_ClearLLab10C_NO-MALIGNANCY"","
45140,6778042,0000045140_BM_6778042_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,82,2024.12.19,2024.12.20,XXX,Bone marrow,Liver cell carcinoma,Acceptable,CD34/SSC,<0.1%,Blasts,1.7×103/μL（dilution:N/Ax）,"14,239 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000045140_MDS.json,2024-12-19T16:54:00.8685436+08:00,68608,2024-12-20T11:42:07.3152364+08:00,0000045140_6778042_Bone marrow_Liver cell carcinoma_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241225\0000045140_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000045140_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 26.4% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 5.6% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region gated by CD34/SSC. However, due to the low number of myeloblasts in the sample, the fluorescence intensity could not be evaluated, and other immunophenotyping results were unremarkable. ※患者骨髓檢體白血球總數<1000/μL且流式細胞儀收集細胞總數不足15,000顆，可能影響分析靈敏度，報告判讀時請小心。",Myeloid blasts comprise less than 0.1% of the total nucleated cells.,BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241225\0000045140_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000045140_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202412\20241225\0000045140_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000045140_MDS.doc""] = ""0000045140_BM_6778042_ClearLLab10C_NO-MALIGNANCY"","
698600,5543372,0698600_BM_5543372_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,82,2024-03-13,2024-03-13,XXX,Bone marrow,MDS/MPN suspected,Acceptable,CD34/SSC,0.2%,Blasts,11.4×103/μL（dilution:N/Ax）,"103,401 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0698600).json,2024-05-22T08:05:20.7747836+08:00,67584,2024-03-13T15:53:16.685+08:00,0698600_5543372_Bone marrow_MDS/MPN suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240313\0698600_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0698600).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.2% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, and HLA-DR. MDS diagnostic flow score: 2 points.","Myeloid blasts comprise approximately 0.2% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,7,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240313\0698600_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0698600).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202403\20240313\0698600_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0698600).doc""] = ""0698600_BM_5543372_ClearLLab10C_NO-MALIGNANCY"","
645126,5665445,0645126_BM_5665445_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.91,,男,83,2024-04-24,2024-04-25,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,91.0%,Blasts,14.7×103/μL（dilution: N/A x）,"99,484 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0645126).json,2024-05-22T08:07:05.5385037+08:00,73728,2024-04-25T14:56:22.1434531+08:00,0645126_5665445_Bone marrow_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240425\0645126_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0645126).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant myeloblast population, comprising approximately 91% of the total nucleated cells. These cells are positive for CD34(partial), MPO, CD33, CD38, CD117, and CD123. Additionally, they are negative for CD10, CD13, CD19, CyCD79a, CyCD3, and HLA-DR.",Immunophenotyping are consistent with acute myeloid leukemia without maturation.,BM,4|5,4,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240425\0645126_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0645126).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202404\20240425\0645126_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(0645126).doc""] = ""0645126_BM_5665445_ClearLLab10C_MALIGNANCY"","
2223914,7244524,0002223914_BM_7244524_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.023,,男,83,2025.03.26,2025.03.27,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,2.3%,Blasts,6.6×103/μL （dilution:N/Ax）,"151,784 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002223914_7244524_MDS.json,2025-03-27T15:58:22.8355095+08:00,71680,2025-03-27T16:05:05.3834366+08:00,0002223914_7244524_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250331\0002223914_7244524_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002223914_7244524_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal myeloblast population comprising approximately 2.3% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, and HLA-DR. These cells also show aberrant expression of CD7. The MDS diagnostic flow score: 3 points. Granulocytes showed abnormal pattern for CD13/CD16, and CD13/CD11b.",Myeloid blasts comprise approximately 2.3% of the total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS).,BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250331\0002223914_7244524_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002223914_7244524_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202503\20250331\0002223914_7244524_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002223914_7244524_MDS.doc""] = ""0002223914_BM_7244524_ClearLLab10C_MALIGNANCY"","
645126,5784420,0645126_BM_5784420_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,83,2024-05-24,2024-05-27,XXX,Bone marrow,AML (post-treatment follow-up),Acceptable,CD34/SSC,0.1%,Blasts,0.2 ×103/μL（dilution:N/Ax）,"30,743 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0645126).json,2024-05-24T15:52:14.6744516+08:00,68608,2024-05-27T09:14:17.4228316+08:00,0645126_5784420_Bone marrow_AML (post-treatment follow-up)_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240527\0645126_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0645126).doc,"Previous FCM results (2024.04.25): acute myeloid leukemia without maturation. Myeloblasts with no predominant aberrancy. Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.1% of total nucleated cells. However, the fluorescence intensity could not be evaluated due to the low number of leukocytes in the sample, and other immunophenotyping results are unremarkable. An unknown cell population (comprising about 4% of the cells analyzed) with very small cell size (based on the forward-scatter signal), brightly expressing CD38 and HLA-DR, are suspected to be debris.",Myeloid blasts comprise approximately 0.1% of the total nucleated cells.,BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240527\0645126_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0645126).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202405\20240527\0645126_AML(T)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-AML(T)(0645126).doc""] = ""0645126_BM_5784420_ClearLLab10C_NO-MALIGNANCY"","
5010574,5365583,5010574_BM_5365583_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,83,2024-01-02,2024-01-02,XXX,Bone marrow,Pancytopenia,Acceptable,CD34/SSC,0.3%,Blasts,0.5×103/μL（dilution:N/Ax）,"94,389 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(5010574).json,2024-05-22T08:01:46.8772752+08:00,68608,2024-01-02T14:02:44.302+08:00,5010574_5365583_Bone marrow_Pancytopenia_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240103\5010574_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(5010574).doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry showed myeloblasts comprise approximately 0.3% of the total nucleated cells, as identified by the CD34-positive gating in the Blast region. These cells exhibited positivity for CD13, CD33, CD38, CD117, CD123, and HLA-DR. Additionally, the analysis showed a T cell population, accounting for about 43% of the cells analyzed, with no aberrant loss or aberrant expression. There was also a B cell population comprise approximately 4% of the cells analyzed, which showed negative for CD5, CD10, and no surface light-chain restriction.",A small proportion of myeloblasts (approximately 0.3%) were detected in the bone marrow.,BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240103\5010574_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(5010574).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240103\5010574_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MPN(5010574).doc""] = ""5010574_BM_5365583_ClearLLab10C_NO-MALIGNANCY"","
1606058,6082313,1606058_BM_6082313_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.99,,男,84,2024.07.26,2024.07.29,XXX,Bone marrow,AML suspected,Acceptable,CD45/SSC,99.3%,Leukemic cells,19.9 ×103/μL（dilution:5x）,"94,113 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_1606058_AML(APL mimic).json,2024-07-29T11:01:52.8459449+08:00,73216,2024-07-31T14:38:01.6392157+08:00,1606058_6082313_Bone marrow_AML suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240731\1606058_AML(APL mimic)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_1606058_AML(APL mimic).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry reveals the presence of a predominant leukemic cell population, comprising approximately 99% of the total nucleated cells. These cells are positive for CD13(dim), CD33, CD38, CD117(partial), CD123, and MPO. Additionally, they are negative for CD34, CD7, CD10, CD19, CyCD79a, CyCD3, and HLA-DR. These cells have intermediate granularity (based on side-scatter signal), and show aberrant expression of CD56.","Immunophenotyping, together with morphological findings in bone marrow, are consistent with acute myeloid leukemia (AML). These findings is like acute promyelocytic leukemia but favor AML with mutated NPM1. Please correlate these findings with the genetic results.",BM,4|5,4,AML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240731\1606058_AML(APL mimic)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_1606058_AML(APL mimic).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202407\20240731\1606058_AML(APL mimic)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_1606058_AML(APL mimic).doc""] = ""1606058_BM_6082313_ClearLLab10C_MALIGNANCY"","
381614,5168306,0381614_PB_5168306_ClearLLab10C_NO-MALIGNANCY,PB,No Malignancy,No Malignancy,,,男,84,2023-10-27,2023-10-30,XXX,Other: 周邊血,MDS-suspected,Acceptable,CD34/SSC,<0.1%,Blasts,3.8×103/μL（dilution: N/Ax）,"101,047 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0381614).json,2024-05-22T07:55:53.9853089+08:00,67072,2023-10-30T11:42:55.954+08:00,0381614_5168306_Other: 周邊血_MDS-suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231030\0381614_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0381614).doc,"Immunophenotyping of peripheral blood leukocytes by flow cytometry revealed that myeloblasts accounted for less than 0.1% of the total nucleated cells in the Blast region However, the fluorescence intensity could not be evaluated due to the low number of myeloblasts in the sample, and other immunophenotyping results are unremarkable. (2) MDS diagnostic flow score: 1 point.","Myeloid blasts comprise less than 0.1% of the total nucleated cells, and there are no myelodysplastic syndrome (MDS)-related features. Please correlate with cytogenetic testing for .",PB,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231030\0381614_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0381614).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231030\0381614_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0381614).doc""] = ""0381614_PB_5168306_ClearLLab10C_NO-MALIGNANCY"","
1470174,6353082,0001470174_BM_6353082_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Chronic Leukemia,0.47,,女,85,2024.09.25,2024.09.25,XXX,Bone marrow,R/O AML,Acceptable,CD45/SSC,47.7%,Other: Monocytes,16.2×103/μL（dilution : 5 x）,"87,542 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001470174_CMML.json,2024-09-26T13:44:16.8651639+08:00,71168,2024-09-26T15:11:12.7310801+08:00,0001470174_6353082_Bone marrow_R/O AML_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240930\0001470174_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001470174_CMML.doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry revealed an abnormal population comprising approximately 47% of all cells analyzed. These monocytes, including both mature and immature stage, are positive for CD4, CD11b, CD14, CD15(dim), CD33, CD38, CD64(bright), CD123, and HLA-DR. Additionally, these cells exhibit aberrant expression of CD56. Immature monocytes comprise approximately 17.8% of total nucleated cells. The MDS diagnostic flow score: 3 points. CD14+/CD16- MO1(classical monocytes): >94%. Granulocytes showed abnormal pattern for CD13/CD11b, CD13/CD16, and decreased SSC.",Immunophenotyping is compatible with chronic myelomonocytic leukemia (CMML).,BM,4|4,-1,CMML,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240930\0001470174_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001470174_CMML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240930\0001470174_CMML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0001470174_CMML.doc""] = ""0001470174_BM_6353082_ClearLLab10C_MALIGNANCY"","
2222817,7023402,0002222817_BM_7023402_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,85,2025.02.10,2025.02.11,XXX,Bone marrow,"ITP, R/O MDS",Acceptable,CD34/SSC,0.3%,Blasts,12.7×103/μL（dilution:N/Ax）,"121,968 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002222817_7023402_MPN.json,2025-02-10T17:19:44.6511266+08:00,69120,2025-02-11T08:50:03.1999199+08:00,"0002222817_7023402_Bone marrow_ITP, R/O MDS_4|4.json",\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250212\0002222817_7023402_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002222817_7023402_MPN.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed a small cell population comprising approximately 0.3% of all cells analyzed, and these myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point. Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise approximately 0.3% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250212\0002222817_7023402_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002222817_7023402_MPN.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2025\202502\20250212\0002222817_7023402_MPN\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0002222817_7023402_MPN.doc""] = ""0002222817_BM_7023402_ClearLLab10C_NO-MALIGNANCY"","
651309,6353083,0000651309_BM_6353083_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,男,86,2024.09.25,2024.09.26,XXX,Bone marrow,"Myelofibrosis, R/O MDS",Suboptimal (reason:  dry tap     ),CD34/SSC,0.9%,Blasts,0.8×103/μL（dilution:N/Ax）,"15,555 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000651309_MF.json,2024-09-26T08:51:04.3850239+08:00,69120,2024-09-26T09:12:03.3135515+08:00,"0000651309_6353083_Bone marrow_Myelofibrosis, R/O MDS_4|4.json",\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240930\0000651309_MF\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000651309_MF.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed myeloblasts identified by CD34/SSC gating in the blast region, accounting for 0.9% of total nucleated cells. These cells are positive for CD13, CD33, CD38, CD117, CD123, CD200, and HLA-DR. The MDS diagnostic flow score: 1 point. Granulocytes showed abnormal pattern for CD13/CD16. Basophils are increased (11%). ※患者骨髓檢體白血球總數<1000/μL且流式細胞儀收集細胞總數不足20,000顆，可能影響分析靈敏度，報告判讀時請小心。","Myeloid blasts comprise approximately 0.9% of the total nucleated cells, and immunophenotyping have no myelodysplastic syndrome (MDS)-related features.",BM,4|4,-1,Non-malignant,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240930\0000651309_MF\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000651309_MF.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202409\20240930\0000651309_MF\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0000651309_MF.doc""] = ""0000651309_BM_6353083_ClearLLab10C_NO-MALIGNANCY"","
5051992,6582938,0005051992_BM_6582938_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.019,,男,87,2024.11.12,2024.11.13,XXX,Bone marrow,R/O MDS,Acceptable,CD34/SSC,1.9%,Blasts,2.9×103/μL（dilution:N/Ax）,"123,773 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0005051992_MDS.json,2024-11-13T15:19:25.9171397+08:00,72704,2024-11-13T15:29:31.0817066+08:00,0005051992_6582938_Bone marrow_R/O MDS_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241120\0005051992_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0005051992_MDS.doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 1.9% of all cells analyzed. These myeloblasts are positive for CD13, CD33, CD34, CD38, CD117, CD123, CD200, and HLA-DR. These cells also show aberrant expression of CD5. The MDS diagnostic flow score: 4 points. Granulocytes showed abnormal pattern for CD13/CD16 and CD13/CD11b, and decreased SSC. Monocytes showed aberrant expression of CD56.",Myeloid blasts comprise approximately 1.9% of the total nucleated cells. Immunophenotyping are compatible with myelodysplastic syndromes (MDS).,BM,4|4,5,MDS,65-89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241120\0005051992_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0005051992_MDS.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202411\20241120\0005051992_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-0005051992_MDS.doc""] = ""0005051992_BM_6582938_ClearLLab10C_MALIGNANCY"","
81918,6164095,0000081918_BM_6164095_ClearLLab10C_MALIGNANCY,BM,Malignancy ,Acute Leukemia,0.51,,男,90,2024.08.14,2024.08.15,XXX,Bone marrow,Leukemia suspected,Acceptable,CD45/SSC,51.6%,Blasts,4.2 ×103/μL（dilution:N/Ax）,"65,191 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000081918_AML.json,2024-08-15T12:24:31.5683989+08:00,71680,2024-08-15T16:01:33.1601929+08:00,0000081918_6164095_Bone marrow_Leukemia suspected_4|5.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202408\20240820\0000081918_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000081918_AML.doc,"Immunophenotyping of the bone marrow aspirate by flow cytometry reveals a predominant myeloblast population, comprising approximately 51% of the total nucleated cells. These cells are positive for CD34(bright), CD13, CD33, CD38, CD117, CD123 and HLA-DR. Additionally, they are negative for CD7, CD10, CD19, MPO, CyCD79a, and CyCD3.",Immunophenotyping are consistent with acute myeloid leukemia with minimal differentiation.,BM,4|5,4,AML,>89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202408\20240820\0000081918_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000081918_AML.doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202408\20240820\0000081918_AML\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單_0000081918_AML.doc""] = ""0000081918_BM_6164095_ClearLLab10C_MALIGNANCY"","
296384,5383468,0296384_BM_5383468_ClearLLab10C_NO-MALIGNANCY,BM,No Malignancy,No Malignancy,,,女,91,2024-01-09,2024-01-10,XXX,Bone marrow,"ITP, R/O MDS",Acceptable,CD34/SSC,0.7%,Blasts,15.6×103/μL（dilution:N/A x）,"138,962 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0296384).json,2024-05-22T08:02:20.9384708+08:00,68608,2024-01-10T09:22:17.111+08:00,"0296384_5383468_Bone marrow_ITP, R/O MDS_4|4.json",\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240110\0296384_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0296384).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry in the blast area shows that myeloblasts account for 0.7%, and they are positive for CD34, CD13, CD33, CD38, CD117, CD123, HLA-DR, and CD7 (partial). Diagnostic flow score: 1 point.",Myeloid blasts comprise approximately 0.7% of the total nucleated cells. Immunophenotyping have no myelodysplastic syndrome (MDS)-related features.,BM,4|4,-1,Non-malignant,>89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240110\0296384_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0296384).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240110\0296384_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0296384).doc""] = ""0296384_BM_5383468_ClearLLab10C_NO-MALIGNANCY"","
661345,5160445,0661345_PB_5160445_ClearLLab10C_NO-MALIGNANCY,PB,No Malignancy,No Malignancy,,,男,94,2023-10-24,2023-10-26,XXX,Other:周邊血,MDS suspected,Acceptable,CD34/SSC,0.1 %,Blasts,1.1 ×103/μL（dilution:N/A x）,"37,867 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0661345).json,2024-05-22T07:55:40.5949111+08:00,67584,2023-10-26T16:42:42.298+08:00,0661345_5160445_Other:周邊血_MDS suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231026\0661345_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0661345).doc,Immunophenotyping of peripheral blood leukocytes by flow cytometry revealed that myeloblasts with normal expression comprised 0.1% of the total nucleated cells in the Blast region. (2) MDS diagnostic flow score: 2 points.,"Myeloid blasts comprise about 0.1% of the total nucleated cells, and there are no myelodysplastic syndrome (MDS)-related features. Please correlate with cytogenetic testing for .",PB,4|4,-1,Non-malignant,>89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231026\0661345_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0661345).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2023\202310\20231026\0661345_MDS\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0661345).doc""] = ""0661345_PB_5160445_ClearLLab10C_NO-MALIGNANCY"","
546231,5365599,0546231_BM_5365599_ClearLLab10C_MALIGNANCY,BM,Malignancy ,"Others: MDS, MPN",0.058,,女,95,2024-01-02,2024-01-02,XXX,Bone marrow,MPN suspected,Acceptable,CD34/SSC,5.8%,Blasts,15.7×103/μL（dilution:3 x）,"120,647 events.",Acceptable,PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0546231).json,2024-05-22T08:01:28.6266346+08:00,71168,2024-01-02T14:19:01.428+08:00,0546231_5365599_Bone marrow_MPN suspected_4|4.json,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240103\0546231_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0546231).doc,"Immunophenotyping of bone marrow aspirate by flow cytometry showed an abnormal population comprising approximately 5.8% of the cells analyzed. These myeloblasts are positive for CD34, CD13, CD33, CD38, CD117, CD123, HLA-DR, and aberrant expression of CD56. MDS diagnostic flow score: 3 points. Granulocytes showed abnormal pattern for CD13/CD11b, CD13/CD16, and CD15/CD10. Monocytes showed aberrant expression of CD56.","Myeloid blasts comprise approximately 5.8% of total nucleated cells. Immunophenotyping are consistent with myelodysplastic syndromes (MDS), please correlate with cytogenetic testing for .",BM,4|4,5,MDS,>89y,,\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240103\0546231_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0546231).doc,1,"[@""\\172.16.153.214\gtp-glp-lab\2F_精準基因暨細胞中心\01.Flow cyotmetry\01.患者報告與分析檔\2024\202401\20240103\0546231_MDS(+NRBC)\PM-20-02-01T v.1 白血病淋巴瘤細胞免疫分型報告紀錄單-MDS(0546231).doc""] = ""0546231_BM_5365599_ClearLLab10C_MALIGNANCY"","